

## PERSONAL INFORMATION



## Michele Caraglia

 via Perciafango 10, 83031, Ariano IRPINO (Avellino)

 +39 081 5665871

 michele.caraglia@unina2.it

**Sex** male | **Date of birth** 18<sup>th</sup> March1966 | **Nationality** Italian

## WORK EXPERIENCE

## Replace with dates (from - to)

29 December 2017-present. Full Professor of Biochemistry, Department of Precision Medicine, University of Campania Luigi Vanvitelli

from 1st July 2012- Adjunct Associate Professor- Sbarro Institute for Cancer Research and Molecular Medicine, Center of Biotechnology Temple University Philadelphia, PA, U.S.A.

1.01.2019 -present President of the Italian Cell Cultures Association AICC

1.01.2015-present Vice-president and Treasurer of the Italian Cell Cultures Association AICC

24.10.2010 -31.12.2014 Secretary and Treasurer of the Italian Cell Cultures Association AICC

1997-present – Professor at the School for the Specialty in Biochemistry and Clinical Chemistry of the Second University of Naples.

1 November 2011-present. Associate Professor of Biochemistry, Department of Biochemistry and Biophysics, University of Campania Luigi Vanvitelli

1 November 2014- present Medical Responsible of the service of nucleotide sequencing in the Unit of Advanced Cytometry at the Policlinico Hospital of the Second University of Naples.

3rd June 2008- 31 October 2011- Assistant Professor of Clinical Biochemistry and Molecular Biology, Department of Biochemistry and Biophysics, Second University of Naples

1 Sept. 2004-3rd June 2008 Senior Investigator of the Experimental Pharmacology Unit of the National Institute of Tumours of Naples. Potentiation of the antitumour activity of cytokines and of inhibitors of isoprenylation – overcoming the escape mechanisms in prostate cancer

2002-2004- Guest researcher at the Department of Biochemistry and Biophysics, Second University of Naples, Naples, Italy. Potentiation of the antitumour activity of cytokines and of inhibitors of isoprenylation – overcoming the escape mechanisms in prostate cancer.

1997-1998- Guest researcher at the University Tor Vergata, Biology Dept. Study of the effects of cytokines on the protein synthesis – escape mechanisms.

1991-1992 - Guest researcher in the Laboratory of IIGB, CNR, Naples. Study of the synthesis of EGF-R protein in cells exposed to IFNa or 8ClcAMP in SCC.

1995-1996- Guest researcher in the Leukemia Unit of CRO, Aviano, Italy. Study of the effects of cytotoxic drugs on EGFR, transferrin receptor and NGFR expression.

## EDUCATION AND TRAINING

Replace with dates (from - to)

2015- National Scientific Qualifications as full professor in Biochemistry

2014- National Scientific Qualifications as full professor in Molecular Biology

1999-2002- PhD degree in Cellular Biochemistry at the Department of Biochemistry and Biophysicssis, Second University of Naples, Naples, Italy. Potentiation of the antitumour activity of cytokines and of inhibitors of isoprenylation – overcoming the escape mechanisms in SCC.

1990-1994 Expecialization in Oncology with magna cum laude, University Federico II of Naples, Italyaly. Study of the activation status of ras in response to pharmacological treatments in SCC – escape mechanisms.

1990- Degree in Medicine with magna cum laude, University Federico II of Naples, Italy. Experimental degree thesis on the study of EGF-R expression modulation induced by IFNa in human squamous cancer cells (SCC).

Mother tongue(s) Italian

Other language(s)

English

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C2	C2	C2

## ADDITIONAL INFORMATION

Editor in Chief

- Translational Medicine Research
- The Open Cancer Immunology

Editorial Board Member of peer reviewed international journals

- Journal Experimental and Clinical Cancer Research
- Recent Patents on Anti-Cancer Drug Discovery
- Journal of Cellular Biochemistry
- Nanomedicine
- Journal of Cellular and Molecular Medicine
- Journal of Interferon and Cytokine Research
- International Journal of Oncology
- Current Cancer Drug Targets
- Expert Opinion on Biological Therapy
- Cancer Biology & Therapy
- In vivo
- Cancer Cell International
- Recent Patents in Anti-Cancer Drug Discovery
- World Journal of Experimental Medicine
- The Open Cancer Journal
- Open Surgical Oncology Journal

## ANNEXES

Editorial Board Member of peer reviewed international journals

- Journal of Cellular Biochemistry
  - Nanomedicine
  - Journal of Cellular and Molecular Medicine
  - Journal of Interferon and Cytokine Research
  - International Journal of Oncology
  - Current Cancer Drug Targets
  - Expert Opinion on Biological Therapy
  - Cancer Biology & Therapy
  - In vivo
  - Cancer Cell International
  - Recent Patents in Anti-Cancer Drug Discovery
  - World Journal of Experimental Medicine
  - The Open Cancer Journal
  - Open Surgical Oncology Journal
- publications

## PUBLICATIONS

(TOTAL IMPACT FACTOR: 7000; H INDEX (SCHOLAR: 63; SCOPUS AND ISI WEB: 53)

1. A. Budillon, P. Tagliaferri, M. Caraglia, M.R. Torrisi, N. Normanno, S. Iacobelli, G. Palmieri, M.P. Stoppelli, L. Frati, A.R. Bianco. "Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells." *Cancer Research*, 51:1294-1299, 1991. IF 7.7
2. P. Correale, A. Procopio, L. Celio, M. Caraglia, G. Genua, V. Coppola, S. Pepe, N. Normanno, I. Vecchio, G. Palmieri, S. Montagnani, P. Tagliaferri, A. R. Bianco. "Phorbol 12-Myristate 13-Acetate induces resistance of human melanoma cells to natural- killer- and lymphokine-activated-killer-mediated cytotoxicity." *Cancer Immunology Immunotherapy*, 34:272-278, 1992. IF 3.5
3. S. Montagnani, G. Giordano-Lanza, E. Di Vaia, R. Vitelli, R. Spera, A. R. Bianco, M. Caraglia, P. Tagliaferri, P. Correale. "Phorbol Myristate Acetate (PMA) induces differentiations and morphological changes in a human adenocarcinoma cell line." *Recent Advances in Cellular Molecular Biology*, Paris, September 1-7, Peeters Press, Leuven, Belgium; 1: 243-247, 1992.
4. P. Correale, P. Tagliaferri, A. Camera, M. Caraglia, V. Coppola, A. Pinto, L. Del Vecchio, B. Rotoli, A. R. Bianco. "CD10/CALLA and adhesion factor expression is predictive for LAK sensitivity of adult B-lineage ALL cells *in vitro*." In: *The Year in Immunology*, Terhost C., Malavasi F., Albertini A. (eds.); Karger, Basel; 7: 90-95, 1993.
5. M. Caraglia, P. Correale, G. Genua, S. Pepe, S. Del Vecchio, G. Esposito, A. R. Bianco, P. Tagliaferri. "Epidermal growth factor (EGFR) and transferrin (TRFR) receptor upregulation is induced by arabinoside cytosine (ARA-C) on human tumor cells." *Cancer Detection and Prevention*, 17: 337-338, 1993. IF 1.4
6. M. Caraglia, P. Tagliaferri, P. Correale, G. Genua, S. Pepe, A. Pinto, S. Del Vecchio, G. Esposito, A. R. Bianco. "Cytosine arabinoside increases the binding of <sup>125</sup>I-labelled epidermal growth factor and <sup>125</sup>I-transferrin and enhances the *in vitro* targeting of human tumour cells with anti- (growth factor receptor) mAb." *Cancer Immunology Immunotherapy*, 37:150-156, 1993. IF 3.5
7. P. Correale, M. Caraglia, A. Procopio, M. R. Marinetti, R. Guerrasi, A. Fabbrocini, A. R. Bianco, P. Tagliaferri. "Transmembrane ion flux modifiers verapamil and ouabain modulate cytotoxic effects of extracellular ATP on human tumor cells *in vitro*." *International Journal of Oncology*, 3: 847-851, 1993. IF 3.1
8. M. Caraglia, A. Pinto, P. Correale, V. Zagonel, G. Genua, A. Leardi, S. Pepe, A. R. Bianco, P. Tagliaferri. "5-Aza-2'-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells." *Annals of Oncology*, 5:269-276, 1994. IF 4.4
9. P. Correale, M. Caraglia, S. Pepe, B. Ricciardi, C. Barile, S. Montagnani, R. Pacelli, A. R. Bianco, P. Tagliaferri. "Phorbol-12-myristate 13-acetate (PMA) induces neuroendocrine differentiation and reverses doxorubicin resistance of human colon carcinoma cells *in vitro*." *International Journal of Oncology*, 4: 423-427, 1994. IF 3.1
10. P. Tagliaferri, P. Correale, M. Mottola, G. de Simone, A. Rea, R. Ascione, A. Morabito, E. Matano, V. Montesarchio, M. Caraglia, G. Tortora, F. Ciardiello, C. Barile, G. Palmieri, A.R.Bianco. "Cardiovascular monitoring of drug-resistant lymphoma patients treated with

EPOCH chemotherapy plus high dose verapamil in continuous infusion".  
Oncology Reports 1:341-44, 1994.

IF 1.4

11. P. Tagliaferri, M. Caraglia, R. Muraro, A. Budillon, A. Pinto, A. R. Bianco. "Pharmacological modulation of peptide growth factor receptor expression on tumor cells as a basis for cancer therapy." Anti-Cancer Drugs 5:379-393, 1994.

IF 2.1

12. G. Palmieri, A. Morabito, A. Rea, M. Caraglia, P. Tagliaferri, A.R. Bianco. "Cytosine Arabinoside (Ara-C) plus Alpha-Interferon (aIFN) determine prolonged remissions in patients with aggressive non Hodgkin lymphoma partially responsive to first-line doxorubicin containing regimens."

British Journal of Haematology 88: 421-423, 1994. IF 3.2

13. M. Caraglia, A. M. Libroia, S. Corradino, V. Coppola, R. Guerrasi, C. Barile, G. Genua, A. R. Bianco and P. Tagliaferri. "a-Interferon induces depletion of intracellular iron content and upregulation of functional transferrin receptors on human epidermoid cancer KB cells." Biochemical and Biophysical Research Communications 203: 281-288, 1994. IF 3

14. P. Tagliaferri, M. Caraglia, P. Correale, C. Barile, A.R. Bianco. "Chemio-immunoterapia del melanoma umano." Temi di Oncologia, Pyxis (Suppl. Rivista USSL N. 4); Palazzo S., Liguori V., Conforti S. (editori); 5: 83-102, 1994.

15. A. Morabito, P. Tagliaferri, A. Rea, M. Caraglia, A.R. Bianco, G. Palmieri. "Ara-C plus a-interferon: a new and effective treatment of non Hodgkin's lymphoma." In:

Proceedings of the XVI International Cancer Congress, Rao R.S., Deo M.G., Sanghvi L.D., Mittra I. (eds.); Monduzzi, Bologna; pp. 2623-2626, 1994.

16. R. Pennarola, A.R. Bianco, P. Tagliaferri, M. Caraglia, R. Guerrasi, A. Di Pace, E. Pennarola. "Aspetti della sorveglianza immunologica anti-tumorale in soggetti esposti alle radiazioni ionizzanti" Archivio di Scienze del Lavoro, Vol. X, n. 2, 1994.

17. P. Correale, M. Giuliano, P. Tagliaferri, R. Guerrasi, M. Caraglia, M.R. Marinetti, T. Iezzi, A.R. Bianco, A. Procopio. "Role of Adenosine 5' Triphosphate activated (LAK) killing of human tumor cells". Res. Commun. Molecular Pathology and Pharmacology 87: 67-69, 1995. IF 1.2

18. F. Ciardiello, V. Damiano, C. Bianco, G. di Isernia, A. Ruggiero, M. Caraglia, P. Tagliaferri, J. Baselga, J. Mendelsohn, A. R. Bianco and G. Tortora. "Cooperative antiproliferative effects of 8-Cl-cAMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells." Clinical Cancer Research 1: 161-167, 1995.

IF 5.6

19. P. Correale, M. Caraglia, A. Fabbrocini, R. Guerrasi, S. Pepe, V. Patella, G. Marone, A. Pinto, A.R. Bianco and P. Tagliaferri. "Bryostatin 1 enhances lymphokine activated killer (LAK) sensitivity and modulates b<sup>1</sup> integrin profile of cultured human tumor cells". Anti-Cancer Drugs 6:285-290, 1995. IF 2.1

20. M. Caraglia, A. Leardi, S. Corradino, F. Ciardiello, A. Budillon, R. Guerrasi, A.R. Bianco, P. Tagliaferri "a-Interferon potentiates epidermal growth factor receptor-mediated effects on human epidermoid carcinoma KB cells" International Journal of Cancer 61: 342-347, 1995. IF 4.4

21. P. Tagliaferri, E. Matano, A. Rea, M. Famiani, F. Ciardiello, G. Tortora, V. Montesarchio, A. Morabito, M. Caraglia, M. De Laurentiis, S. De Placido, G. Palmieri, A.R. Bianco "Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's lymphoma patients non-eligible for standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) combination" Oncology Reports 2: 365-368, 1995. IF 1.4

22. M. Caraglia, A. Passeggi, P. Tagliaferri, A. Leardi, A.R. Bianco, M.G. D'Angelo, S. Beninati, A. Abbruzzese. "Effects of interferon a2-recombinant (IFNa) on the expression of epidermal growth factor receptor (EGF-R) and on eukaryotic initiation factor-5A (eIF-5A) synthesis in human epidermoid cancer KB cells." Italian Journal of Biochemistry, 45/1: 22-24, 1996. IF 0.1

23. P. Tagliaferri, G. Tortora, R. Guerrasi, V. Damiano, A. Ruggiero, D. Morelli, M. Caraglia, R. Bianco, G. di Isernia, S. Pepe, C.L. Arteaga, B.C. Langton-Webster, A.R. Bianco and F. Ciardiello. "Differential sensitivity to non-MHC-restricted rIL-2 activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or PKA subunits" Clinical Cancer Research, 2: 207-214, 1996. IF 5.6

24. M. Caraglia, A. Leardi, B. Ricciardi, M. de Laurentiis, M. L. Lentini Graziano, E. Matano, S. De Placido, A. R. Bianco, P. Tagliaferri "a-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies" International Journal of Oncology, 8: 847-850, 1996. IF 3.1

25. P. Tagliaferri, P. Correale, M. Mottola, G. de Simone, V. Montesarchio, E. Matano, A. Rea, A. Morabito, M. Famiani, F. Ciardiello, G.

- Tortora, M. Caraglia, C. Barile, G. Palmieri and A. R. Bianco "High dose recombinant interleukin-2/Verapamil combination in advanced cancer"  
European Journal of Cancer, 8 (32A): 1436-1437, 1996. IF 3.3
26. G. Palmieri, A. Morabito, A. Rea, R. Lauria, V. Montesarchio, E. Biondi, M. Caraglia, P. Tagliaferri, A.R. Bianco "Maintenance therapy with recombinant interferon alpha-2B (alFN) in prognostically unfavourable aggressive non Hodgkin's lymphomas (NHL)".  
Oncology Reports, 3: 733-735, 1996. IF 1.4
27. A. Passeggio, M. Caraglia, S. Beninati, A. Leardi, P. Tagliaferri and A. Abbruzzese. "Hypusine biosynthesis is correlated to ornithine decarboxylase activity in KB cells."  
Italian Journal of Biochemistry, 46 : 32-35, 1997. IF 0.1114
28. M. Caraglia, A. Passeggio, S. Beninati, A. Leardi, L. Nicolini, S. Impronta, A. Pinto, A.R. Bianco, P. Tagliaferri, A. Abbruzzese. "Interferon a2 recombinant and epidermal growth factor modulate proliferation and hypusine synthesis in human epidermoid cancer KB cells."  
Biochemical Journal, 324: 737-741, 1997. IF 4.3
29. M. Caraglia, A. Leardi, S. Impronta, V. Perin, B. Ricciardi, C. Arra, P. Ferraro, A. Fabbrocini, A. Pinto, A.R. Bianco, P. Tagliaferri. "Transient exposure to cytarabine increases peptide growth factor receptor expression and tumorigenicity of melanoma cells".  
Anticancer Research, 17: 2369-2376, 1997. IF 1.4
30. P. Tagliaferri, C. Barile, M. Caraglia, R. Guerrasi, D. Morelli, B. Ricciardi, A. Martignetti, M.T. Librera, E. Matano, M. Famiani, A. Della Vecchia, G. Catalano, G. Palmieri, P. Correale, A.R. Bianco "Daily low dose subcutaneous recombinant Interleukin-2 by alternate weekly administration: antitumor activity and immunomodulatory effects."  
American Journal of Clinical Oncology (CCT), 21: 48-53, 1998. IF 1.7
31. P. Tagliaferri, R. Guerrasi, M. Caraglia, D. Morelli, A. Fabbrocini, P. Correale, A. R. Bianco. "Tumour cell resistance to non-MHC restricted lymphocytes: molecular mechanisms and clinical implications."  
Cancer Immunology Immunotherapy, 46:121-127, 1998. IF 3.5
32. A. LEARDI, M CARAGLIA, C. SELLERI, S. PEPE, C. PIZZI, R. NOTARO, A. FABBROCINI, S. DE LORENZO, M. MUSICÒ, A. ABRUZZESE, A.R. BIANCO AND P. TAGLIAFERRI. "DESFERIOXAMINE INCREASES IRON DEPLETION AND APOPTOSIS INDUCED BY ARA-C ON HUMAN MYELOID LEUKEMIC CELLS."  
BRITISH JOURNAL OF HAEMATOLOGY, 102(3): 746-752, 1998. IF 3.2
33. S. Beninati, V. Gentile, M. Caraglia, A. Lentini, P. Tagliaferri, and A. Abbruzzese "Tissue transglutaminase expression affects hypusine metabolism in BALB-C 3T3 cells"  
FEBS Letters, 437: 34-38, 1998. IF 3.9
34. M. Caraglia, M. Marra, G. Giuberti, A. Leardi, S. Pepe, A. Fabbrocini, S. Beninati, A. R. Bianco, P. Tagliaferri and A. Abbruzzese "Desferioxamine And Arabinoside Cytosine (Ara-C) Effects On Iron Depletion, Apoptosis And Hypusine Levels In Human Myeloid Leukemic Cells." In: COST917 "Biogenically active amines in food", Vol. III "Biologically active amines in food processing and amines produced by bacteria, and polyamines and tumour growth." Bardocz, S., Koninkx, J., Grillo, M. and White, A., eds. Luxembourg, pp. 106-113, 1999.
35. P. Stiuso, G. Colonna, R. Ragone, M. Caraglia, J.W.B. Hershey, S. Beninati, and A. Abbruzzese "Structural organization of the human eukaryotic initiation factor 5A precursor and its site-directed variant LYS 50→ARG"  
Amino Acids, 16: 91-106, 1999. IF 2
36. G. Lupoli, G. Vitale, M. Caraglia, M.R. Fittipaldi, A. Abbruzzese, P. Tagliaferri, A.R. Bianco "Familial non medullary thyroid carcinoma: a new clinical entity"  
The Lancet, 20: 637-639, 1999. IF 10.23
37. M. Caraglia, E. Di Gennaro, D. Barbarulo, M. Marra, P. Tagliaferri, A. Abbruzzese, A. Budillon "Upregulated EGF receptors undergo to rapid internalization and ubiquitin-dependent degradation in human cancer cells exposed to 8-Cl-cAMP"  
FEBS Letters, 447: 203- 209, 1999. IF 3.9
38. A. Budillon, E. Di Gennaro, M. Caraglia, D. Barbarulo, A. Abbruzzese and P. Tagliaferri "8-Cl-cAMP antagonizes mitogen-activated protein kinase activation and cell growth stimulation induced by epidermal growth factor"  
British Journal of Cancer, 81: 1134-1141, 1999. IF 3.8
39. M. Caraglia, A. Abbruzzese, A. Leardi, S. Pepe, A. Budillon, G. Baldassarre, C. Selleri, S. De Lorenzo, A. Fabbrocini, G. Giuberti, G. Vitale, G. Lupoli, A. R. Bianco, and P. Tagliaferri "Interferon-a induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor" Cell Death and Differentiation, 6: 773-780, 1999.  
IF 8.2

40. M. Caraglia, P. Tagliaferri, A. Budillon, and A. Abbruzzese "Post-translational modifications of eukaryotic initiation factor-5A (eIF-5A) as a new target for anti-cancer therapy" Advances in Experimental and Medicine Biology, Plenum Press, New York, 1999, pp 187-198.  
IF 0.7
41. G. Vitale, P. Tagliaferri, M. Caraglia, E. Rampone, A.Ciccarelli, A.R.Bianco, A. Abbruzzese, G. Lupoli "Slow release lanreotide in combination with *interferon- $\alpha$ -2b* in the treatment of symptomatic advanced medullary thyroid carcinoma: an algorithmic approach to the definition of response"  
Journal of Clinical Endocrinology and Metabolism, 85, 983-988, 2000. IF 5.8
42. A. Lentini, F. Autuori, P. Mattioli, M. Caraglia, A. Abbruzzese, S. Beninati "Evaluation of the efficacy of potential antineoplastic drugs on tumour metastasis by computer-assisted image analysis"  
European Journal of Cancer, 36(12):1572-1577, 2000. IF 3.3
43. A. Lentini, F.Vidal-Vanaclocha, F. Facchiano, M. Caraglia, A. Abbruzzese and S. Beninati "Theophylline administration markedly reduces hepatic and pulmonary implantation of B16-F10 melanoma cells in mice"  
Melanoma Research, 10: 435-443, 2000. IF 1.7
44. M. Caraglia, A. Budillon, G. Vitale, G. Lupoli, P. Tagliaferri and A. Abbruzzese "Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation"  
European Journal of Biochemistry 267: 3919-3936, 2000. IF 3.3
45. M. Caraglia, M. Marra, G. Giuberti, A.M. D'Alessandro, A. Budillon, S. Del Prete, A. Lentini, S. Beninati and A. Abbruzzese. "The role of eukaryotic initiation factor 5A in the control of cell proliferation and apoptosis".  
Amino Acids, 20, 91-104, 2001. IF 2
46. G. Vitale, M. Caraglia, A. Ciccarelli, P. Tagliaferri, A. Abbruzzese, G. Lupoli. Current approaches in the therapy of thyroid medullary carcinoma.  
Cancer 91(9):1797-1808, 2001. IF 4.4
47. S. Del Prete, D. Russo, M. Caraglia, G. Giuberti, M. Marra, G. Vitale, G. Lupoli, A. Abbruzzese, E. Capasso "Percutaneous ethanol injection of autonomous thyroid nodules with a volume larger than 40 ml: three years of follow-up".  
Clinical Radiology 56(11): 895-901, 2001. IF 1.5
48. Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V, Abbruzzese A, Lupoli G  
"Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer".  
British Journal of Cancer 15, 84,1586-90, 2001. IF 3.8
49. A. M. Facchiano, P. Stiuso, M. L. Chiusano, M. Caraglia, G. Giuberti, M. Marra, A. Abbruzzese, G. Colonna  
"Homology modelling of the human eukaryotic initiation factor 5A (eIF-5A)".  
Protein Engineering 14, 881-890, 2001. IF 3.8
50. C. Pizzi, M. Caraglia, M. Cianciulli, A. Libroia, A. Fabbrocini, A. Martignetti, E. Matano, A. Contegiacomo, S. Del Prete, A. Abbruzzese, A. Martignetti, P. Tagliaferri And A. R. Bianco Low doses recombinant il-2 induces psychological changes: monitoring by minnesota multiphasic personality inventory (MMPI). Anticancer Research, 22(2A): 727-732, 2002. IF 1.4
51. G. Vitale, A. Ciccarelli, M. Caraglia, M. Galderisi, R. Rossi, S. Del Prete, A. Abbruzzese, G. Lupoli "Comparison of two provocative tests for calcitonin in medullary thyroid carcinoma: omeprazole versus pentagastrin"  
Clinical Chemistry, 48(9), 1505-1510, 2002 . IF 6.5
52. M. Caraglia, M. Marra, G. Giuberti, A.M. D'alessandro, S. Beninati, A. Lentini, S. Pepe, M. Boccellino And A. Abbruzzese "Theophylline-induced apoptosis is paralleled by Protein Kinase A-dependent tissue transglutaminase activation in cancer cells."  
Journal of Biochemistry, 132(1):45-52, 2002. IF 2.3
53. S. Del Prete, M. Caraglia, D. Russo, G. Vitale, G. Giuberti, M. Marra, A. M. D'Alessandro, G. Lupoli, R. Addeo, G. Facchini, R. Rossiello, A. Abbruzzese, E. Capasso. "Percutaneous ethanol injection efficacy in the treatment of large symptomatic thyroid cystic nodules: ten-year follow-up on a large series."  
Thyroid, 12, 815-821, 2002. IF 2.4
54. M. Caraglia, P. Tagliaferri, M. Marra, G. Giuberti, A. Budillon, E. Di Gennaro, S. Pepe, G. Vitale, S. Impronta, P. F. Tassone, S. Venuta, A. R. Bianco and A. Abbruzzese "EGF activates an inducible survival response via the RAS -> ERK-1/2 pathway to counteract interferon- $\alpha$ -mediated apoptosis in epidermoid cancer cells".

- Cell Death and Differentiation 10 (1), 218-229, 2003. IF 8.2
55. C. Esposito, M. Marra, G. Giuberti, A. M. D'Alessandro, R. Porta, A. Cozzolino, M. Caraglia\*, A. Abbruzzese. Ubiquitination of tissue transglutaminase is modulated by interferon alpha in human lung cancer cells.
- Biochemical Journal, 370, 205-212, 2003. IF 4.3  
\*CORRESPONDING AUTHOR
56. E. Di Gennaro, M. Barbarino, F. Bruzzese, S. De Lorenzo, M. Caraglia, A. Abbruzzese, S. Pepe, A. Avallone, G. Cornella, F. Caponigro, and A. Budillon. Critical role of both p27<sup>KIP1</sup> and p21<sup>CIP1/WAF1</sup> in the antiproliferative effect of ZD1839, an EGF receptor tyrosine kinase inhibitor in head and neck squamous carcinoma cells. Journal of Cellular Physiology, 195, 139-150, 2003. IF 5.2
57. M. Caraglia , M. Marra, G. Giuberti, A.M. D'alessandro, P. Tassoni, S. Venuta, P. Tagliaferri, A. Abbruzzese "The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by Interferona and EGF in human cancer cells" Journal of Biochemistry, 133, 757-765, 2003. IF 2.3
58. P. Tassone, P. Tagliaferri, C. Palmieri, C. Visconti, E. Galea, M. Caraglia, A. M. D'Alessandro, A. Abbruzzese, A. Goel, C. R. Boland and S. Venuta "Zoledronic acid induces anti-proliferative activity and caspase-9-mediated apoptotic death of human pancreatic cancer cells" British Journal of Cancer, 88, 1971-1978, 2003. IF 3.8
59. M. Boccellino, G. Giuberti, L. Quagliuolo, M. Marra, L. Servillo, A. Abbruzzese and M. Caraglia. "Apoptosis induced by interferon-a is paralleled by caspase3-mediated cleavage of gelsolin in human epidermoid cancer cells" Journal of Cellular Physiology, 201:71-83, 2004. IF 5.2
60. M. Caraglia, G. Vitale, M. Marra, S. Del Prete, A. Lentini, A. Budillon, S. Beninati, A. Abruzzese "Translational and Post-translational modifications of proteins as a new mechanism of action of Alpha-Interferon" Amino Acids 26: 409-417, 2004. IF 2
61. A. Lamberti, M. Caraglia, O. Longo, M. Marra, A. Abbruzzese, P. Arcari "The translation elongation factor 1a in tumorigenesis, signal transduction and apoptosis" Amino acids 26(4):443-8 2004. IF 2
62. A. Lentini, A. Abruzzese, M. Caraglia, M. Marra, S. Bennati "Protein-polyamine conjugation by transglutaminase in cancer cell differentiation: review artiche". Amino acids 26(4):331-337, 2004 IF 2
63. M. Caraglia\*, G. Vitale, A. Colao, M. Marra, Alfredo Budillon, P. Tagliaferri and Alberto Abbruzzese "Alpha-Interferon And Its Effects On Signalling Pathways Within Cells". Current Protein Peptide Science 5(6):475-85, 2004. IF 3  
\*CORRESPONDING AUTHOR
64. M. Caraglia\*, A.M. D'alessandro, M. Marra, G. Giuberti, G. Vitale, C. Visconti, A Colao, S. Del Prete, P. Tagliaferri, P. Tassone, A. Budillon, S. Venuta and A. Abruzzese "The farnesyl transferase inhibitor R115777 (Zamestra®) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa ®) and Pamidronate". Oncogene, 23(41):6900-13, 2004. IF 6.3  
\*CORRESPONDING AUTHOR
65. R. Addeo, M. Caraglia\*, R. Costanzo, V. Faiola, L. Montella, A. Abbruzzese and S. Del Prete "Oxaliplatin/Rituximab combination in the treatment of intermediate-low grade NHL of elderly patients" Oncology Reports, 12: 135-140, 2004 IF 1.4  
\*CORRESPONDING AUTHOR
66. E. Di Gennaro, F. Bruzzese, M. Caraglia, A. Abbruzzese, A. Budillon "Acetylation of proteins as novel target for antitumor therapy" Amino Acids 26(4):435-441, 2004 IF 2
67. P. Correale, S. Messinese, M. Caraglia, S. Marsili, A. Piccolomini, R. Petriol, F. Ceciarini, L. Micheli, C. Nencini, A. Neri, G. Vuolo, A. Guarneri, A. Abbruzzese, S. Del Prete, G. Giorgi and G. Francini "A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma" British Journal of Cancer, 90:1710-1714, 2004 IF 3.8
68. R. Addeo, F. Casale, M. Caraglia\*, V. D'Angelo, S. Crisci, A. Abbruzzese, M.T. Di Tullio, P. Indolfi. "Glucocorticoids Induce G(1)

Arrest of Lymphoblastic Cells Through Retinoblastoma Protein Rb1 Dephosphorylation in Childhood Acute Lymphoblastic Leukemia In Vivo."

Cancer Biology & Therapy, 3(5):470-6. 2004

IF 3.3

\*CORRESPONDING AUTHOR

69. F. Mancinelli, M. Caraglia, A. Abbruzzese, G. D'ambrosio, R. Massa & E. Bismuto "non-thermal effects of electromagnetic fields at mobile phone frequency on the refolding of an intracellular protein: myoglobin." Journal of Cellular Biochemistry, 93(1):188-96, 2004.

IF 3

70. F. Casale, V. D'Angelo, R. Addeo, M. Caraglia, S. Crisci, R. Rondelli, M.T. Di Tullio and P. Indolfi. "P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia." Oncology Reports, 12(6):1201-1208, 2004.

IF 1.4

71. L. Montella, M. Caraglia\*, A. Abbruzzese, A. Soricelli, S. Del Prete, G. Squame, M. Salvatore "Molecular technology and the recombinant TSH have changed the diagnostics of thyroid carcinoma with positive I-131 whole body scan but low serum thyroglobulin." Experimental Molecular Medicine, 36(3):268-273, 2004.

IF 1.7

\* CORRESPONDING AUTHOR

72. G. Vitale, R. Pivonello, D. Ferone, MC De Martino, RS Auriemma, M. Caraglia, A. Abbruzzese, G. Lombardi, A. Colao The role of somatostatin receptors in the medical treatment of acromegaly. Dig Liver Dis. 36 Suppl 1:S55-9, 2004.

IF 1.4

73. P. Tagliaferri, M. Caraglia, A. Budillon, M. Marra, G. Vitale, C. Visconti, S. Masciari, P. Tassone, A. Abbruzzese and S. Venuta "New pharmacokinetic and pharmacodynamic tools for Interferon a treatment of human cancer". Cancer Immunology Immunotherapy, 54(1):1-10 2005.

IF 3.5

74. L. Montella, M. Caraglia\*, R. Addeo, R. Costanzo, V. Faiola, A. Abbruzzese and S. Del Prete. Atrial fibrillation following chemotherapy for diffuse large B-cell-IIIE staged-gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease). Annals of Haematology, 84(3):192-3, 2005.

IF 1.3

\*CORRESPONDING AUTHOR

75. M. Caraglia\*, M. Marra, G. Pelaia, R. Maselli, M. Caputi, S. A. Marsico, A. Abbruzzese "Alpha-Interferon And Its Effects On Signal Transduction Pathways"

Journal of Cellular Physiology, 202(2):323-35, 2005.

IF 5.2

\*CORRESPONDING AUTHOR

76. G. Pelaia, G. Cuda, A. Vatrella, L. Gallelli, M. Caraglia, M. Marra, A. Abbruzzese, M. Caputi, R. Maselli, F. S. Costanzo, and S. A. Marsico "Mitogen-activated protein kinases and asthma"

Journal of Cellular Physiology, 202(3):642-653, 2005.

IF 5.2

77. M. Caraglia\*, Montella L, Addeo R, Costanzo R, Faiola V, Del Prete S, Baldi F, Baldi A, Abbruzzese A, Alloisio M. "Conditions suggesting lymphoma: case 2. Mediastinal liposarcoma in a patient with previous testicular cancer". Journal of Clinical Oncology, 23(16):3844-6, 2005.

IF 9.8

\*CORRESPONDING AUTHOR

78. L. Postiglione, G. Di Domenico, M. Caraglia\*, M. Marra, G. Giuberti, L. del Vecchio, S. Montagnani, M. Macrì, E. M. Bruno, A. Abbruzzese, G. Rossi "Differential expression and cytoplasm/membrane distribution of endoglin (CD105) in human tumour cell lines: implications in the modulation of cell proliferation" International Journal of Oncology, 26(5): 1193-1201, 2005

IF 3.1

\*CORRESPONDING AUTHOR

79. M. Caraglia\*, A. Budillon, P. Tagliaferri, M. Marra, A. Abbruzzese, F. Caponigro. "Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications"

Current Drug Targets, 6(3):301-23, 2005.

IF 4.1

\* CORRESPONDING AUTHOR

80. P. Tagliaferri, P. Tassone, S. Blotta, C. Visconti, F. Grillone, A. Budillon, M. Caraglia, and S. Venuta. "Antitumor Therapeutic Strategies Based On The Targeting Of Epidermal Growth Factor-Induced Survival Pathways" Current Drug Targets, 6(3):289-300, 2005.

IF 4.1

81. A. Budillon, F. Bruzzese, E. Di Gennaro, M. Caraglia "Multiple-targets drugs: inhibitors of Heat shock protein 90 and of Histone

## Deacetylase"

Current Drug Targets 6(3):337-51, 2005.

IF 4.1

82. M. Caraglia\*, G. Giuberti, M. Marra, E. Di Gennaro, G. Facchini, F. Caponigro, RV Iaffaioli, A. Budillon, A. Abruzzese "Docetaxel Induces p53-Dependent Apoptosis And Synergizes With Farnesyl Transferase Inhibitor R115777 In Human Epithelial Cancer Cells"

Frontiers in Bio-Science 10:2566-75, 2005.

IF 3.2

\*CORRESPONDING AUTHOR

83. F. Caponigro, R. Formato, M. Caraglia, N. Normanno, R. V. Iaffaioli "Monoclonal antibodies targeting EGFR and VEGF with a focus on head and neck tumors"

Current Opinion in Oncology, 17(3):212-217, 2005.

IF 4

84. M. Caraglia\*, M. Marra, F. Mancinelli, G. D'ambrosio, R. Massa, A. Giordano, A. Budillon, A. Abbruzzese & E. Bismuto "Electromagnetic fields at mobile phone frequency induce apoptosis and inactivation of the multi-chaperone complex in human epidermoid cancer cells"

Journal Of Cellular Physiology, 204(2):539-48, 2005.

IF 5.2

\*CORRESPONDING AUTHOR

85. R. Addeo, M. Caraglia\*, A. Baldi, V. D'angelo, F. Casale, S. Crisci, A. Abbruzzese, B. Vincenzi, M. Campioni, M. T. Di Tullio, P. Indolfi, "Prognostic role of bcl-xL and p53 in Childhood Acute Lymphoblastic Leukemia (ALL)"

Cancer Biology &amp; Therapy 4(1):32-8, 2005

IF 3.3

\*CORRESPONDING AUTHOR

86. RV Iaffaioli, R Formato, A Tortoriello, S Del Prete, M Caraglia, G Pappagallo, A Pisano, F Fanelli, G Ianniello, S Cigolari, C Pizza, O Marano, G Pezzella, T Pedicini, A Febbraro, P Incoronato, L Manzione, E Ferrari, N Marzano, S Quattrin, S Pisconti, G Nasti, G Giotta, G Colucci. "Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer".

British Journal of Cancer 92(9):1621-5, 2005.

IF 3.8

87. P. Correale, F. Fulfaro, S. Marsili, G. Cicero, E. Bajardi, C. Intrivici, G. Vuolo, A. F. Carli, M. Caraglia, S. Del Prete, N. Gebbia, and G. Francini. Gemcitabine (GEM) plus oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer.

Cancer Chemotherapy &amp; Pharmacology 56(6):563-8, 2005.

IF 2.2

88. L. Montella, M. Caraglia, A. Abbruzzese, A. Soricelli, M. Caputi, G. Squame, M. Salvatore, S. Del Prete, G. Calmieri "Mediastinal Images Resembling Thymus Following 131-I Treatment for Thyroid Cancer"

Monaldi Arch Chest Dis 63(2):114-7, 2005.

89. G. Facchini, F. Fiore, M. Caraglia\*, R. D'Angelo, G. Nasti, F. Caponigro, R. Formato, A. Budillon, R. V. Iaffaioli A liver angioma colonized by colon cancer cells in a patient with two primitive localizations by colon adenocarcinoma: biologic, diagnostic and therapeutic implications.

Annals of Oncology 16(12):1980-1981, 2005.

IF 4.4

\*CORRESPONDING AUTHOR

90. Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete S, Tsang KY, Micheli L, Nencini C, La Placa M, Montagnani F, Terrosi C, Caraglia M, Formica V, Giorgi G, Bonmassar E, Francini G. "Dendritic Cell-Mediated Cross-Presentation of Antigens Derived from Colon Carcinoma Cells Exposed to a Highly Cytotoxic Multidrug Regimen with Gemcitabine, Oxaliplatin, 5-Fluorouracil, and Leucovorin, Elicits a Powerful Human Antigen-Specific CTL Response with Antitumor Activity in Vitro."

Journal of Immunology 175(2):820-828, 2005.

IF 6.5

91. Caraglia M\*, Marra M, Budillon A, Meo G, Ricciardiello F, Bismuto E, Brachelente G, Francini G, Giordano A, Correale P, Abbruzzese A. Chemotherapy Regimen GOLF Induces Apoptosis in Colon Cancer Cells through Multi-Chaperone Complex Inactivation and Increased Raf-1 Ubiquitin-Dependent Degradation.

Cancer Biology &amp; Therapy 4(10):1159-67, 2005.

IF 3.2

\*CORRESPONDING AUTHOR

92. Caraglia M\*, Beninati S, Giuberti G, D'Alessandro AM, Lentini A, Abbruzzese A, Bove G, Landolfi F, Rossi F, Lampa E, Costantino M. Alternative therapy of earth elements increases the chondroprotective effects of chondroitin sulfate in mice.

Experimental Molecular Medicine 37(5):476-81, 2005.

IF 1.7

\*CORRESPONDING AUTHOR

93. M. Caraglia, M. Marra, G. Meo, S.R. Addeo, P. Tagliaferri and A. Budillon: EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy.

Recent patents on Anti-Cancer Drug Discovery, 1(2):209-222, 2006.

94. D. Santini, G. Schiavon, S. Angeletti, B. Vincenzi, S. Gasparro, C. Grilli, A. La Cesa, V. Virzi, V. Leoni, A. Budillon, S. R. Addeo, M.

Caraglia, G. Dicuonzo and G. Tonini "Last Generation of Amino-Bisphosphonates (N-BPs) and Cancer Angiogenesis: A New Role for These Drugs?"

Recent Patents on Anti-Cancer Drug Discovery, 1(3): 383-396, 2006.

95. M. Caraglia, M. Marra, C. Leonetti, G. Meo, S.R. Addeo, F. Buzzese, P. Tagliaferri G. Zupi, A. Abbruzzese, A. Budillon: The farnesyl-transferase R115777 and the aminobisphosphonate zoledronic acid synergize on the apoptosis and on the growth inhibition of human cancers cells.

Haematologica reports 2(3):27-28, 2006.

96. Caraglia M., Dicitore A., Giuberti G., Cassese D., Lepretti M., Carteni M., Abbruzzese A., Stiuso P. Effects of VIP and VIP-DAP on proliferation and lipid peroxidation metabolism in human KB cells.

Ann N Y Acad Sci. 1070:167-72, 2006.

IF 2

97. Caraglia M., Tassone P., Marra M., Budillon A., Venuta S., Tagliaferri P. Targeting Raf-kinase: molecular rationales and translational issues.

Ann Oncol. Jun;17(suppl.7):vii124-vii127, 2006.

IF 4.4

98. Santini D., Caraglia M., Vincenzi B., Holen I., Scarpa S., Budillon A., Tonini G. Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates.

Nature Clinical Practice Oncology. 3(6):325-38, 2006.

99. Santini D, Graziano F, Catalano V, Di Seri M, Testa E, Baldelli AM, Giordani P, La Cesa A, Spalletta B, Vincenzi B, Russo A, Caraglia M, Virzi V, Cascinu S, Tonini G. Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial.

BMC Cancer. 6:125, 2006.

IF 2

100. Mancinelli F, Caraglia M\*, Budillon A, Abbruzzese A, Bismuto E. Molecular dynamics simulation and automated docking of the pro-apoptotic Bax protein and its complex with a peptide designed from the Bax-binding domain of anti-apoptotic Ku70.

Journal of Cellular Biochemistry. 1;99(1):305-18, 2006.

IF 3.0

\*CORRESPONDING AUTHOR

101. Caraglia M\*, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates.

Endocrine-Related Cancer. 13(1):7-26, 2006.

IF 4.6

\*CORRESPONDING AUTHOR

102. Santini D, Vincenzi B, Hannon RA, Brown JE, Dicuonzo G, Angeletti S, La Cesa A, Coleman RE, Tonini G, Budillon A, Caraglia M\*, Holen I. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.

Oncology Reports. 5(5):1351-7, 2006.

IF 1.4

\*CORRESPONDING AUTHOR

103. Buzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, Caraglia M, Tagliaferri P, Budillon A. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.

Clinical Cancer Research 12(2):617-25, 2006.

IF 5.7

104. P. Magistrelli, R. Coppola, G. Tonini, B. Vincenzi, D. Santini, D. Borzomati, F. Vecchio, S. Valeri, F. Castri, A. Antinori, G. Nuzzo, M. Caraglia\* and A. Picciocchi. "Apoptotic Index or a combination of Bax/Bcl-2 expression correlates with survival after resection of pancreatic adenocarcinoma"

Journal of Cellular Biochemistry. 97(1):98-108, 2006.

IF 3.0

\*CORRESPONDING AUTHOR

105. Caraglia M\*, Addeo R, Costanzo R, Montella L, Faiola V, Marra M, Abbruzzese A, Palmieri G, Budillon A, Grillone F, Venuta S, Tagliaferri P, Del Prete S. Phase II study of temozolamide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours.

Cancer Chemotherapy and Pharmacology. 57(1):34-9, 2006.

IF 2.2

\*CORRESPONDING AUTHOR

106. Addeo R, Caraglia M, Faiola V, Capasso E, Vincenzi B, Montella L, Guerrasi R, Caserta L, Del Prete S. Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of Life.

BMC Cancer. 25;7:18, 2007.

IF 2

107. Palmieri G, Marino M, Salvatore M, Budillon A, Meo G, Caraglia M\*, Montella L. Cetuximab is an active treatment of metastatic and chemorefractory thymoma.

Frontiers in Bioscience. 12:757-61, 2007.

IF 3.2

\*CORRESPONDING AUTHOR

108. Santini D, Vincenzi B, Caraglia M, Tonini G. A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss.  
Annals of Oncology. 18(1):201-2, 2007.

IF 4.4

109. Ottaiano A, Facchini G, Nasti G, Budillon A, Caraglia M. \* Phase II studies of anticancer chemotherapy: indirect evidence of poor quality.  
Annals of Oncology. 18(2):403, 2007.

IF 4.4

\*CORRESPONDING AUTHOR

110. Naviglio S, Spina A, Marra M, Sorrentino A, Chiosi E, Romano M, Impronta S, Budillon A, Illiano G, Abbruzzese A, Caraglia M\*. Adenylate cyclase/cAMP pathway downmodulation counteracts apoptosis induced by IFN-alpha in human epidermoid cancer cells.  
Journal of Interferon and Cytokine Research. 27(2):129-36, 2007.

IF 2.1

\*CORRESPONDING AUTHOR

111. Palmieri G, Montella L, Aiello C, Barbieri F, Di Vizio D, Schulz S, Beninati S, Budillon A, Caraglia M\*, Insabato L, Florio T. Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract.  
Amino Acids. 2007 Feb 6.

IF 2

\*CORRESPONDING AUTHOR

112. Lentini A, Provenzano B, Caraglia M, Shevchenko A, Abbruzzese A, Beninati S. Impairment of the metastatic activity of melanoma cells by transglutaminase-catalyzed incorporation of polyamines into laminin and Matrigel.  
Amino Acids. 2007 Mar 14.

IF 2

113. Lamberti A, Longo O, Marra M, Tagliaferri P, Bismuto E, Fiengo A, Visconti C, Budillon A, Rapp UR, Wang E, Venuta S, Abbruzzese A, Arcari P, Caraglia M\*. C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A.  
Cell Death and Differentiation. 14(5):952-62, 2007.

IF 8.2

\*CORRESPONDING AUTHOR

114. Lentini A, Mattioli P, Provenzano B, Abbruzzese A, Caraglia M, Beninati S. Role of the FAD-dependent polyamine oxidase in the selective formation of N(1),N(8)-bis(gamma- glutamyl)spermidine protein cross-links(1).  
Biochemical Society Transactions. 35(2):396-400, 2007.

IF 1.4

115. Caraglia M\*, Marra M, Leonetti C, Meo G, D'Alessandro AM, Baldi A, Santini D, Tonini G, Bertieri R, Zupi G, Budillon A, Abbruzzese A. R115777 (Zarnestra(R))/Zoledronic acid (Zometa(R)) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.  
Journal of Cellular Physiology. 211(2):533-43, 2007.

IF 5.2

\*CORRESPONDING AUTHOR

116. Addeo R, Crisci S, D'Angelo V, Vincenzi B, Casale F, Pettinato G, Donofrio V, Boldrini R, Alaggio R, Collini P, Bertorelle R, Di Tullio MT, Caraglia M\*, Terenziani M, Lo Curto M, Indolfi P. Bax mutation and overexpression inversely correlate with immature phenotype and prognosis of childhood germ cell tumors.  
Oncology Reports. 17(5):1155-61, 2007.

IF 1.4

\*CORRESPONDING AUTHOR

117. Ottaiano A, Budillon A, Normanno N, Iaffaioli V, Caraglia M\* A multidisciplinary approach is required to increase the quality of phase II/III clinical studies on biotherapies in oncology.  
Annals of Oncology. 18(5):960-1, 2007.

IF 4.4

\*CORRESPONDING AUTHOR

118. Donadelli M, Costanzo C, Beghelli S, Scupoli MT, Dandrea M, Bonora A, Piacentini P, Budillon A, Caraglia M, Scarpa A, Palmieri M. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.  
Biochemical and Biophysics Acta 1773(7):1095-106, 2007

IF 4.4

119. Nasti G, Facchini G, Caraglia M\*, Franco R, Mura AL, Staiano M, Budillon A, Iaffaioli RV, Ottaiano A. Concomitant occurrence of facial cutaneous and parotid gland metastases from rectal cancer after preoperative chemoradiotherapy.  
Onkologie. 2007 Jun;30(6):324-6. 1.724

IF 1.724

\*CORRESPONDING AUTHOR

120. Vetrano A, Addeo R, Russo I, Meo G, De Rosa G, D'Anna F, Caraglia M\*. A case of clear renal cell cancer associated to meningioma and verrucous carcinoma of frontal region in an old patient.  
J Exp Clin Cancer Res 26(1):157-9, 2007

IF 0.869

\*CORRESPONDING AUTHOR

121. M. Marra, E. Agostinelli , G. Tempera, A. Lombardi, G. Meo, A. Budillon , G. Giuberti, A. Abbruzzese and M. Caraglia\*. Anticancer drugs and hyperthermia enhance cytotoxicity induced by polyamine enzymatic oxidation products.

Amino Acids 2007 Jul 4.

IF 2

\*CORRESPONDING AUTHOR

122. Avallone A, Di Gennaro E, Bruzzese F, Laus G, Delrio P, Caraglia M, Pepe S, Comella P, Budillon A. Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.

Anticancer Drugs. 18(7):781-91, 2007.

123. A. Budillon, E. Di Gennaro, F. Bruzzese, M. Rocco, G. Manzo, M. Caraglia. Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents.

Recent patents on anti-cancer drug discovery 2(2):119-134, 2007

124. P. Tagliaferri, P. Tassone, A. Pietragalla, M.S. Rotundo, V. Barbieri, A. Budillon, M. Caraglia\*, F.S. Costanzo, S. Venuta. Chemoprevention of BRCA1-related breast and ovarian tumours.

Recent patents on anti-cancer drug discovery 2(2):165-173, 2007

\*CORRESPONDING AUTHOR

125. M. Sagristani, M. Caraglia\*, M.R. Villa, A. Lucania, M. Esposito, L. Petriccione, S. Impronta, M. Marra, G. Iannaci, R. Rossiello, L. Mastrullo. Concomitant occurrence of a primari renal NHL and of a papillary urothelial ureter cancer.

Journal of Experimental & Clinical Cancer Research. 26(2):291-2, 2007. IF 0.869

\*CORRESPONDING AUTHOR

126. Facchini G, Caraglia M\*, Santini D, Nasti G, Ottaiano A, Striano S, Maiolino P, Ruberto M, Fiore F, Tonini G, Budillon A, Iaffaioli RV, Zeppetella GL. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).

Journal of Experimental & Clinical Cancer Research. 26(3):307-12, 2007. IF 0.869

\*CORRESPONDING AUTHOR

127. Colone M, Calcabrini A, Toccacieli L, Bozzuto G, Stringaro A, Gentile M, Cianfriglia M, Ciervo A, Caraglia M, Budillon A, Meo G, Arancia G, Molinari A. The Multidrug Transporter P-Glycoprotein: A Mediator of Melanoma Invasion?

Journal of Investigative Dermatology. 2007 Oct 18.

IF 4.5

128. Addeo R, Faiola V, Guerrasi R, Montella L, Vincenzi B, Capasso E, Cennamo G, Rotundo MS, Tagliaferri P, Caraglia M, Del Prete S. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women >/=65 years of age.

Cancer Chemotherapy and Pharmacology. 2007 Oct 9.

IF 2.363

129. Facchini G, Caraglia M\*, Nasti G, Ottaiano A, Franco R, La Mura A, Fulciniti F, Libutti M, Ruberto M, Marra M, Budillon A, Iaffaioli R. Small tumor of the medial breast presenting with a contralateral lymph node involvement detected on positron emission tomography scan.

Annals of Oncology. 18(9):1579-80, 2007.

IF 5.179

\*CORRESPONDING AUTHOR

130. Addeo R, Nocera V, Faiola V, Vincenzi B, Ferraro G, Montella L, Guerrasi R, Rossi E, Cennamo G, Tonini G, Capasso E, Santini D, Caraglia M, Del Prete S. Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report.

Support Care Cancer. 2007 Aug 14.

IF 1.905

131. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, Schiavon G, Angeletti S, Uzzalli F, Caraglia M, Dicuonzo G, Tonini G. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.

Clinical Cancer Research. 13(15 Pt 1):4482-6, 2007.

IF 6.177

132. Caraglia M\*, Marra M, Visconti C, D'Alessandro AM, Budillon A, Meo G, Arra C, Barbieri A, Rapp UR, Baldi A, Tassone P, Venuta S, Abbruzzese A, Tagliaferri P. The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways.

International Journal of Cancer. 121(10):2317-30, 2007.

IF 4.693

\*CORRESPONDING AUTHOR

133. Chiosi E, Spina A, Sorrentino A, Romano M, Sorvillo L, Senatore G, D'Auria R, Abbruzzese A, Caraglia M\*, Naviglio S, Illiano G. Change in TNF-alpha receptor expression is a relevant event in doxorubicin-induced H9c2 cardiomyocyte cell death.

Journal of Interferon and Cytokine Research. 27(7):589-97, 2007.

IF 2.472

\*CORRESPONDING AUTHOR

134. Caraglia M\*, Carteni M, Dicitore A, Cassese D, De Maria S, Ferranti P, Giuberti G, Abbruzzese A, Stiuso P. Experimental study on vasoactive intestinal peptide (VIP) and its diaminopropyl bound (VIP-DAP) analog in solution. *Amino Acids.* 2007 Jul 6. IF 2.104  
\*CORRESPONDING AUTHOR
135. Addeo R, Montella L, Baldi A, Cennamo G, Guerrasi R, Faiola V, Caraglia M, Del Prete S. Atypical cutaneous lymphoid hyperplasia induced by chemotherapy in a patient with advanced colon carcinoma. *Clinical Colorectal Cancer.* 6(10):728-30, 2007. IF 2.5
136. Caraglia M\*, Marra M, Budillon A. Highlights of the annual meeting of the Italian Association for Cell Cultures (AICC): new drug delivery strategies and technological platforms for diagnosis and therapy of tumors (Part I) 6 - 7 December 2007, Naples, Italy. *Expert Opin Biol Ther.* 8(6):845-54, 2008 IF 2.7  
\*CORRESPONDING AUTHOR
137. Laezza C, Fiorentino L, Pisanti S, Gazzero P, Caraglia M, Portella G, Vitale M, Bifulco M. Lovastatin induces apoptosis of k-ras-transformed thyroid cells via inhibition of ras farnesylation and by modulating redox state. *J Mol Med.* 86(12):1341-51, 2008. IF 5.192
138. Montella L, Addeo R, Caraglia M, Faiola V, Guerrasi R, Vincenzi B, Palmeri A, Capasso E, Nocera V, Tarantino L, Ariete M, Martorelli A, Del Prete S. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience. *Oncol Rep.* 20(2):385-90, 2008. IF 1.686
139. M. Marra, A. Lombardi, E. Agostinelli, G. Giuberti, S. Zappavigna, G. Tempera, G. Vitale, M. Bifulco, A. Abbruzzese, M. Caraglia\*. Bovine serum amine oxidase and spermine potentiate docetaxel and interferon- $\alpha$  effects in inducing apoptosis on human cancer cells through the generation of oxidative stress. *BBA - Molecular Cell Research* 1783(12):2269-78, 2008 IF 6.09  
\*CORRESPONDING AUTHOR
140. M. Marra, D. Santini, G. Tonini, G. Meo, S. Zappavigna, G. Facchini, A. Morabito, A. Abbruzzese, G. Carteni, A. Budillon, M. Caraglia\*. Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid *Europena Journal of Cancer suppl* 6:79-85, 2008 IF 4.167  
\*CORRESPONDING AUTHOR
141. Addeo R, De Rosa C, Faiola V, Leo L, Cennamo G, Montella L, Guerrasi R, Vincenzi B, Caraglia M\*, Del Prete S. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. *Cancer* 113(9):2524-31, 2008 IF 4.4  
\*CORRESPONDING AUTHOR
142. Vincenzi B, Patti G, Galluzzo S, Pantano F, Venditti O, Santini D, Ruzzo A, Schiavon G, Caraglia M, Marra M, Graziano F, Tonini G. Interleukin 1beta-511T gene (IL1beta) polymorphism is correlated with gastric cancer in the Caucasian population: results from a meta-analysis. *Oncol Rep.* 20(5):1213-20, 2008 IF 1.4
143. Lepretti M, Costantini S, Ammirato G, Giuberti G, Caraglia M\*, Facchiano AM, Metafora S, Stiuso P. The N-terminal 1-16 peptide derived in vivo from protein seminal vesicle protein IV modulates alpha-thrombin activity: potential clinical implications. *Exp Mol Med.* 40(5):541-9, 2008 IF 1.7  
\*CORRESPONDING AUTHOR
144. Neri P, Tagliaferri P, Di Martino MT, Calimeri T, Amodio N, Bulotta A, Ventura M, Eramo PO, Visconti C, Arbitrio M, Rossi M, Caraglia M, Munshi NC, Anderson KC, Tassone P. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. *Br J Haematol.* 143(4):520-31, 2008 IF 3.2
145. Vitale G, Caraglia M, van Koetsveld PM, Maroni P, Marra M, Colao A, Lamberts SW, Cavagnini F, Hofland LJ. Potential role of type I interferons in the treatment of pituitary adenomas. *Rev Endocr Metab Disord.* 10(2):125-33, 2009 IF 1.9
146. M. Caraglia\*, M. Marra, S.W.J. Lamberts, S. Zappavigna, G. Misso, F. Cavagnini, A. Abbruzzese, L.J. Hofland, G. Vitale. Emerging strategies to strengthen the anti-tumour activity of type I IFNs: overcoming survival pathways. *Current Cancer Drug Targets* 9(5):690-704, 2009 IF 5.677  
\*CORRESPONDING AUTHOR
147. Naviglio S, Caraglia M\*, Abbruzzese A, Chiosi E, Di Gest D, Marra M, Romano M, Sorrentino A, Sorvillo L, Spina A, Illiano G. Protein

kinase A as a biological target in cancer therapy.

Expert Opin Ther Targets. 13(1):83-92, 2009

\*CORRESPONDING AUTHOR

148. Vitale G, Gentilini D, Abbruzzese A, Caraglia M\* Pyk2 and Cyr61 at the cross-road of cAMP-dependent signalling in invasiveness and neuroendocrine differentiation of prostate cancer.

Cancer Biol Ther. 8(3), 2009.

\*CORRESPONDING AUTHOR

149. Correale P, Miano ST, Remondo C, Migali C, Rotundo MS, Macrì P, Tagliaferri P, Tassone P, Caraglia M, Gotti G, Francini G. Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine.

Cancer Biol Ther. 8(6), 2009

IF 3.3

150. Addeo R, Caraglia M\*, Del Prete S. Highlights of regional meeting of Italian Southern Oncological Group (GOIM): focus on hepatocellular carcinoma: biological and clinical background, therapeutic guide-lines and perspectives. 7 November 2008, Naples, Italy.

Expert Opin Investig Drugs. 18(3):373-8, 2009

IF 3.6

\*CORRESPONDING AUTHOR

151. D'Angelo V, Crisci S, Casale F, Addeo R, Giuliano M, Pota E, Finsinger P, Baldi A, Rondelli R, Abbruzzese A, Caraglia M\*, Indolfi P. High Erk-1 activation and Gadd45a expression as prognostic markers in high risk pediatric haemolymphoproliferative diseases.

J Exp Clin Cancer Res. 19;28:39, 2009

IF 1.5

\*CORRESPONDING AUTHOR

152. Tassone P, Di Martino MT, Ventura M, Pietragalla A, Cucinotto I, Calimeri T, Bulotta A, Neri P, Caraglia M\*, Tagliaferri P. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo.

Cancer Biol Ther. 8(7):648-53, 2009

IF 3.3

\*CORRESPONDING AUTHOR

153. Addeo R, Caraglia M\*, Del Prete S Highlights of the Pananemia National meeting of the Italian Southern Oncological Group (GOIM): pharmacological and molecular treatment of cancer-induced anemia. Sorrento, Italy, 19-20 December 2008.

Expert Opin Pharmacother. 10(6):1089-93, 2009

IF 1.7

\*CORRESPONDING AUTHOR

154. Fogli S, Caraglia M. Genotype-based therapeutic approach for colorectal cancer: state of the art and future perspectives.

Expert Opin Pharmacother 10(7):1095-108, 2009

IF 1.7

155. Montella L, Addeo R, Faiola V, Cennamo G, Guerrasi R, Capasso E, Mamone R, Caraglia M, Del Prete S. Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports.

J Exp Clin Cancer Res 13;28:7, 2009

IF 1.5

156. Marra M, Santini D, Meo G, Vincenzi B, Zappavigna S, Baldi A, Rosolowski M, Tonini G, Loeffler M, Lupu R, Abbruzzese A, Budillon A, Caraglia M\*. CYR61 down-modulation potentiates the anticancer effects of zoledronic acid in androgen independent prostate cancer cells.

International Journal of Cancer 125(9):2004-13, 2009

IF 4.7

\*CORRESPONDING AUTHOR

157. Marra M, Giudice A, Arra C, Vitale G, Castiglioni S, Nasti G, Lombardi A, Ottaiano A, Facchini G, Iaffaioli RV, Abbruzzese A, Caraglia M\*. Target-based agents in neo-adjuvant treatment of liver metastases from colo-rectal cancer: Secret weapons in anti-cancer war?

Cancer Biology and Therapy 8(18):1709-18, 2009

IF 2.761

\*CORRESPONDING AUTHOR

158. Marra M, Abbruzzese A, Addeo R, Del Prete S, Tassone P, Tonini G, Tagliaferri P, Santini D, Caraglia M\*. Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects.

Current Cancer Drug Targets, 9(7):791-800, 2009

IF 4.187

\*CORRESPONDING AUTHOR

159. Naviglio S, Di Gesto D, Romano M, Sorrentino A, Illiano F, Sorvillo L, Abbruzzese A, Marra M, Caraglia M, Chiosi E, Spina A, Illiano G. Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer cells.

Cancer Biology and Therapy 8(12):1183-90, 2009.

IF 2.761

160. Montella L, Addeo R, Palmieri G, Caraglia M, Cennamo G, Vincenzi B, Guerrasi R, Mamone R, Faiola V, Frega N, Capasso E, Maiorino L, Leonardo D, Pizza C, Montesarchio V, Del Prete S. Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series.

Cancer Chemother Pharmacol. Sep 16, 2009

IF 2.363

161. Facchini G, Perri F, Caraglia M, Pisano C, Striano S, Marra L, Fiore F, Aprea P, Pignata S, Iaffaioli RV. New treatment approaches in

- renal cell carcinoma.  
Anticancer Drugs 20(10):893-900, 2009. IF 2.376
162. Addeo R, De Santi MS, Del Prete S, Caraglia M. Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug. Cancer Chemother Pharmacol. 64(5):863-6, 2009. IF 2.3
163. Montella L, Addeo R, Guerrasi R, Cennamo G, Faiola V, Capasso E, Caraglia M\*, Prete SD. Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide. Eur J Cancer Care (Engl). Jun 22, 2009 IF 1.138  
**\*CORRESPONDING AUTHOR**
164. Pantano F, Baldi A, Santini D, Vincenzi B, Borzomati D, Vecchio FM, Castri F, Antinori A, Caraglia M, Magistrelli P, Coppola R, Tonini G. MUC2 but not MUC5 expression correlates with prognosis in radically resected pancreatic cancer patients. Cancer Biol Ther 8(11):996-9, 2009. IF 2.761
165. Sirangelo I, Iannuzzi C, Vilasi S, Irace G, Giuberti G, Misso G, D'Alessandro A, Abbruzzese A, Caraglia M\*. W7FW14F apomyoglobin amyloid aggregates-mediated apoptosis is due to oxidative stress and AKT inactivation caused by Ras and Rac. J Cell Physiol. 221(2):412-23, 2009. IF 5.2  
**\*CORRESPONDING AUTHOR**
166. Caraglia M\*, Santini D. Target therapy of bone metastases and tumours. Curr Cancer Drug Targets 9(7):789-90, 2009 IF 4.187  
**\*CORRESPONDING AUTHOR**
167. Santini D, Fratto ME, Vincenzi B, Napoli N, Galluzzo S, Tantardini M, Abbruzzese A, Caraglia M, Tonini G. Denosumab: the era of targeted therapies in bone metastatic diseases. Curr Cancer Drug Targets 9(7):834-42, 2009. IF 4.187
168. Tassone P, Tagliaferri P, Rossi M, Calimeri T, Bulotta A, Abbruzzese A, Caraglia M, Neri P. Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy. Curr Cancer Drug Targets 9(7):854-70, 2009 IF 4.187
169. Del Prete SD, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, Piai G, Febbraro A, Tarantino L, Capasso E, Palmieri G, Guerrasi R, Bianco M, Mamone R, Savastano C, Pisano A, Vincenzi B, Sabia A, D'Agostino A, Faiola V, Addeo R. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother Pharmacol 66(5):837-44. 2010 IF 2.3
170. Costantino M, Giuberti G, Caraglia M, Lombardi A, Misso G, Abbruzzese A, Ciani F, Lampa E. Possible antioxidant role of SPA therapy with chlorine-sulphur-bicarbonate mineral water. Amino Acids 36:161–165 2009 IF 2.1
171. Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, Miragliuolo A, Guerrasi R, Lanna M, Cennamo G, Faiola V, Del Prete S. Randomized Phase III Trial on Gemcitabine Versus Mytomycin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance. J Clin Oncol. 28(4):543-8, 2010 IF 13.6
172. Caraglia M\*, Marra M, Naviglio S, Botti G, Addeo R, Abbruzzese A. Zoledronic acid: an unending tale for an anti-resorptive agent. Expert Opinion on Pharmacotherapy, 11(1):141-54, 2010 IF 2.077  
**\*CORRESPONDING AUTHOR**
173. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M, Colucci G, Del Prete S, Tonini G. Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib. Oncologist. 15(1):85-92, 2010. IF 6.63
174. Franco R, Cantile M, Scala S, Catalano E, Cerrone M, Scognamiglio G, Pinto A, Chiofalo MG, Caracò C, Anniciello AM, Abbruzzese A, Caraglia M\*, Botti G. Histomorphologic parameters and CXCR4 mRNA and protein expression in sentinel node melanoma metastasis are correlated to clinical outcome. Cancer Biology and Therapy 9(6):423-9. 2010 IF 2.761  
**\*CORRESPONDING AUTHOR**
175. Gazzero P, Malfitano AM, Proto MC, Santoro A, Pisanti S, Caruso MG, Notarnicola M, Messa C, Laezza C, Misso G, Caraglia M, Bifulco M. Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin. Oncol Rep 23(1):171-5, 2010 IF 1.4
176. Stiuso P, Giuberti G, Lombardi A, Dicitore A, Limongelli V, Cartenì M, Abbruzzese A, Caraglia M\*. gamma-Glutamyl 16-diaminopropane derivative of vasoactive intestinal peptide: a potent anti-oxidative agent for human epidermoid cancer cells.

- Amino Acids. 39(3):661-70. 2010 IF 2  
\*CORRESPONDING AUTHOR
177. Giudice A, Caraglia M\*, Marra M, Abbruzzese A, Arra C. Circadian rhythms and Haematopoiesis. Expert Opinion on Therapeutic Targets 14(5):567-75. 2010 IF 4.038  
\*CORRESPONDING AUTHOR
178. Correale P, Remando C, Migali C, Marra M, Misso G, Arcuri FP, Del Vecchio MT, Carducci A, Loiacono L, Tagliaferri P, Abbruzzese A, Arancini G, Caraglia M\*. Cytotoxic drugs up-regulate Epidermal Growth Factor Receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted Antibody-Dependent-Cell-mediated-Cytotoxicity (ADCC). European Journal of Cancer 46(9):1703-11. 2010 IF 4.475  
\*CORRESPONDING AUTHOR
179. Santini D, Vincenzi B, Adamo V, Addeo R, Fusco V, Russo A, Montemurro F, Roato I, Redana S, Lanzetta G, Satolli MA, Berruti A, Leoni V, Galluzzo S, Antimi M, Ferraro G, Rossi M, Del Prete S, Valerio MR, Marra M, Caraglia M, Tonini G. Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. Oncology Reports 25(6):1545-8. 2011 IF 1.4
180. Addeo R, Caraglia M, Cerbone D, Frega N, Cimmino G, Abbruzzese A, Del Prete S. Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer. Expert Rev Anticancer Ther 10(4):499-505. 2010 IF 2.493
181. Santini D, Spoto C, Loupakis F, Vincenzi B, Silvestris N, Cremolini C, Canestrari E, Graziano F, Galluccio N, Salvatore L, Caraglia M, Zito FA, Colucci G, Falcone A, Tonini G, Ruzzo A. High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. Ann Oncol. 21(7):1565. 2010 IF 5.179
182. Santini D, Schiavon G, Vincenzi B, Cass CE, Vasile E, Manazza AD, Catalano V, Baldi GG, Lai R, Rizzo S, Giacobino A, Chiusa L, Caraglia M, Russo A, Mackey J, Falcone A, Tonini G. Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC). Curr Cancer Drug Targets.11(1):123-9. 2011 IF 4.187
183. Salzano G, Marra M, Porru M, Zappavigna S, Abbruzzese A, La Rotonda MI, Leonetti C, Caraglia M, De Rosa G. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. Int J Pharm. 17;403(1-2):292-7. 2011 IF 2.962
184. Montella L, Addeo R, Caraglia M, Del Prete S. Latest developments in targeted therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 10(10):1635-46. 2010 IF 2.493
185. Vitale G, Fatti LM, Prolo S, Girola A, Caraglia M, Marra M, Abbruzzese A, Gerli G, Mari D. Screening for hypothyroidism in older hospitalized patients with anemia: a new insight into an old disease. J Am Geriatr Soc. 58(9):1825-7. 2010. IF 3.656
186. Ostacolo L, Marra M, Ungaro F, Zappavigna S, Maglio G, Quaglia F, Abbruzzese A, Caraglia M. In vitro anticancer activity of docetaxel-loaded micelles based on poly(ethylene oxide)-poly(epsilon-caprolactone) block copolymers: Do nanocarrier properties have a role? J Control Release. 148(2):255-63. 2010 IF 4.756
187. Pannone G, Bufo P, Santoro A, Franco R, Aquino G, Longo F, Botti G, Serpico R, Cafarelli B, Abbruzzese A, Caraglia M\*, Papagerakis S, Lo Muzio L. WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors. Oncol Rep.24(4):1035-41. 2010. IF 1.4  
\*CORRESPONDING AUTHOR
188. Addeo R, Sgambato A, Cennamo G, Montella L, Faiola V, Abbruzzese A, Capasso E, Leo L, Botti G, Caraglia M, Del Prete S. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer. 10(4):301-6. 2010. IF 2.427
189. Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, Licchetta A, Addeo R, Volterrani L, Gotti G, Rotundo MS, Tassone P, Sperlongano P, Abbruzzese A, Caraglia M, Tagliaferri P, Francini G. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. Cancer Biol Ther.9(9):685-93, 2010. IF 2.761
190. Addeo R, Caraglia M, De Santi MS, Montella L, Abbruzzese A, Parlato C, Vincenzi B, Carraturo M, Faiola V, Genovese M, Cennamo G, Del Prete S. A new schedule of fotemustine in temozolamide-pretreated patients with relapsing glioblastoma. J Neurooncol. 102(3):417-24. 2011 IF 2.75

191. Campioni M, Severino A, Manente L, Tuduce IL, Toldo S, Caraglia M, Crispi S, Ehrmann M, He X, Maguire J, De Falco M, De Luca A, Shridhar V, Baldi A. The serine protease HtrA1 specifically interacts and degrades the tuberous sclerosis complex 2 protein. *Mol Cancer Res.* 8(9):1248-60, 2010. IF 4.16

192. Facchini G, Caraglia M\*, Morabito A, Marra M, Piccirillo MC, Bochicchio AM, Striano S, Marra L, Nasti G, Ferrari E, Leopardi D, Vitale G, Gentilini D, Tortoriello A, Catalano A, Budillon A, Perrone F, Iaffaioli RV. Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: Phase I ZANTE trial. *Cancer Biol Ther.* 10(6):543-548 2010. IF 2.761

\*CORRESPONDING AUTHOR

193. Ungaro F, Conte C, Ostacolo L, Maglio G, Barbieri A, Arra C, Misso G, Abbruzzese A, Caraglia M, Quaglia F. Core-shell biodegradable nanoassemblies for the passive targeting of docetaxel: features, antiproliferative activity and in vivo toxicity. *Nanomedicine.* Sep 1. 8(5):637-46 2012 IF 6.202

194. Di Martino MT, Arbitrio M, Leone E, Guzzi PH, Rotundo MS, Ciliberto D, Tomaino V, Fabiani F, Talarico D, Sperlongano P, Doldo P, Cannataro M, Caraglia M, Tassone P, Tagliaferri P. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. *Cancer Biol Ther.* 12(9):780-7. 2011 IF 2.761

195. Grieco P, Franco R, Bozzuto G, Toccacieli L, Sgambato A, Marra M, Zappavigna S, Migaldi M, Rossi G, Striano S, Marra L, Gallo L, Cittadini A, Botti G, Novellino E, Molinari A, Budillon A and Caraglia M\*. Uroternsin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. *Journal of Cellular Biochemistry.* 112(1):341-53, 2011. IF 3.112

\*CORRESPONDING AUTHOR

196. Faggiano A, Ramundo V, Dicitore A, Castiglioni S, Borghi MO, Severino R, Ferolla P, Crinò L, Abbruzzese A, Sperlongano P, Caraglia M, Ferone D, Hofland L, Colao A, Vitale G. Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. *J Cell Mol Med.* 1582-4934 2011 IF 4.608

197. Perdonà S, Di Lorenzo G, Autorino R, Buonerba C, De Sio M, Setola SV, Fusco R, Ronza FM, Caraglia M, Ferro M, Petrillo A. Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection. *Urol Oncol.* Sep 7. [Epub ahead of print] 2011 IF 3.17

198. Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M, Agresti M, Caraglia M, Sperlongano P. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. *J Transl Med.* 9:171. Review. 2011 IF 3.51

199. Ferro M, Giuberti G, Zappavigna S, Perdonà S, Facchini G, Sperlongano P, Porto S, Di Lorenzo G, Buonerba C, Abbruzzese A, Altieri V, Caraglia M. Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms. *Oncol Rep.* 27(2):409-15. 2012 IF 1.686

200. Caraglia M, Park MH, Wolff EC, Marra M, Abbruzzese A. eIF5A isoforms and cancer: two brothers for two functions? *Amino Acids.* Dec 3. [Epub ahead of print] 2011 IF 4.106

201. Colombino M, Sperlongano P, Izzo F, Tatangelo F, Botti G, Lombardi A, Accardo M, Tarantino L, Sordelli I, Agresti M, Abbruzzese A, Caraglia M, Palmieri G BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. *Cell Death Dis.* 19;3:e259. 2012

202. Caraglia M, Addeo R. Editorial: target therapy in brain tumours and metastases. *Curr Cancer Drug Targets.* 12(3):185. 2012 IF 4.771

203. Caraglia M, De Rosa G, Salzano G, Santini D, Lamberti M, Sperlongano P, Lombardi A, Abbruzzese A, Addeo R. Nanotech revolution for the anti-cancer drug delivery through blood-brain-barrier. *Curr Cancer Drug Targets.* 12(3):186-96. 2012 IF 4.771

204. Caraglia M, Marra M, Misso G, Lamberti M, Salzano G, De Rosa G, Abbruzzese A. Tumour-specific uptake of anti-cancer drugs: the future is here. *Curr Drug Metab.* 13(1):4-21. 2012 IF 3.896

205. De Rosa G, Salzano G, Caraglia M, Abbruzzese A. Nanotechnologies: a strategy to overcome blood-brain barrier. *Curr Drug Metab.* 13(1):61-9. 2012 IF 3.896
206. Sanges C, Scheuermann C, Zahedi RP, Sickmann A, Lamberti A, Migliaccio N, Baljuls A, Marra M, Zappavigna S, Rapp U, Abbruzzese A, Caraglia M, Arcari P. Raf kinases mediate the phosphorylation of eukaryotic translation elongation factor 1A and regulate its stability in eukaryotic cells. *Cell Death Dis.* 1;3:e276. 2012
207. Galdiero M, Caraglia M. Nanotechnological and biotechnological strategies for drug delivery. *Curr Drug Metab.* 13(1):2-3. 2012 IF 3.896
208. Ciliberto D, Prati U, Roveda L, Barbieri V, Staropoli N, Abbruzzese A, Caraglia M, Di Maio M, Flotta D, Tassone P, Tagliaferri P. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. *Oncol Rep.* 27(6):1849-56. 2012 IF 1.686
209. Torricelli P, Caraglia M, Abbruzzese A, Beninati S.  $\gamma$ -Tocopherol inhibits human prostate cancer cell proliferation by up-regulation of transglutaminase 2 and down-regulation of cyclins. *Amino Acids.* Mar 30. [Epub ahead of print] 2012 IF 4.166
210. Misso G, Giuberti G, Lombardi A, Grimaldi A, Ricciardello F, Giordano A, Tagliaferri P, Abbruzzese A, Caraglia M. Pharmacological inhibition of HSP90 and ras activity as a new strategy in the treatment of HNSCC. *J Cell Physiol.* May 7. doi: 10.1002/jcp.24112. [Epub ahead of print] 2012 IF 3.986
211. Troiani T, Vecchione L, Martinelli E, Capasso A, Costantino S, Ciuffreda LP, Morgillo F, Vitagliano D, D'Aiuto E, De Palma R, Tejpar S, Van Cutsem E, De Lorenzo M, Caraglia M, Berrino L, Ciardiello F. Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. *Br J Cancer.* 106(10):1648-59. 2012 IF 4.346
212. Botta C, Bestoso E, Apollinari S, Cusi MG, Pastina P, Abbruzzese A, Sperlongano P, Misso G, Caraglia M, Tassone P, Tagliaferri P, Correale P. Immune-modulating Effects of the Newest Cetuximab-based Chemoimmunotherapy Regimen in Advanced Colorectal Cancer Patients. *J Immunother.* 35(5):440-7. 2012 IF 3.593
213. Rossi M, Di Martino MT, Morelli E, Leotta M, Rizzo A, Grimaldi A, Misso G, Caraglia M. Molecular targets for the treatment of multiple myeloma. *Curr Cancer Drug Targets* Jun 5 2012 IF 4.771
214. Addeo R, Caraglia M, Frega N, Del Prete S. Two faces for Janus: recombinant human erythropoiesis-stimulating agents and cancer mortality. *Expert Rev Hematol.* 2(5):513-5. 2009 IF 0.459
215. Franco R, Boscia F, Gigantino V, Marra L, Esposito F, Ferrara D, Pariante P, Botti G, Caraglia M, Minucci S, Chieffi P. GPR30 is overexpressed in post-puberal testicular germ cell tumors. *Cancer Biol Ther.* 11(6):609-13. 2011 IF 2.907
216. Marra M, Salzano G, Leonetti C, Tassone P, Scarsella M, Zappavigna S, Calimeri T, Franco R, Liguori G, Cigliana G, Ascani R, La Rotonda MI, Abbruzzese A, Tagliaferri P, Caraglia M, De Rosa G. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. *Nanomedicine.* 7(6):955-64. 2011 IF 6.202
217. Santini D, Vincenzi B, Adamo V, Addeo R, Fusco V, Russo A, Montemurro F, Roato I, Redana S, Lanzetta G, Satolli MA, Berruti A, Leoni V, Galluzzo S, Antimi M, Ferraro G, Rossi M, Del Prete S, Valerio MR, Marra M, Caraglia M, Tonini G. Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. *Oncol Rep.* 25(6):1545-8. 2011 IF 1.686
218. Correale P, Botta C, Basile A, Pagliuchi M, Licchetta A, Martellucci I, Bestoso E, Apollinari S, Addeo R, Misso G, Romano O, Abbruzzese A, Lamberti M, Luzzi L, Gotti G, Rotundo MS, Caraglia M, Tagliaferri P. Phase II trial of bevacizumab and dose/dense

chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. Cancer Biol Ther. 12(2):112-8. 2011 IF 2.907

219. Caraglia M, Giuberti G, Marra M, Addeo R, Montella L, Murolo M, Sperlongano P, Vincenzi B, Naviglio S, Prete SD, Abbruzzese A, Stiuso P. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis. 2:e150. 2011

220. Donadelli M, Dando I, Zaniboni T, Costanzo C, Dalla Pozza E, Scupoli MT, Scarpa A, Zappavigna S, Marra M, Abbruzzese A, Bifulco M, Caraglia M, Palmieri M. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis. Apr 28;2:e152. 2011

221. Addeo R, Caraglia M. Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera? Expert Opin Investig Drugs. 20(7):881-95. Review. 2011 IF 4.337

222. Correale P, Botta C, Cusi MG, Del Vecchio MT, De Santi MM, Gori Savellini G, Bestoso E, Apollinari S, Mannucci S, Marra M, Abbruzzese A, Aquino A, Turriziani M, Bonmassar L, Caraglia M, Tagliaferri P. Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. Int J Cancer. 130(7):1577-89. 2012 IF 4.926

223. Buzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, Di Gennaro E, Budillon A. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol. 226(9):2378-90. 2011 IF 3.986

224. Lamberti A, Sanges C, Chambery A, Migliaccio N, Rosso F, Di Maro A, Papale F, Marra M, Parente A, Caraglia M, Abbruzzese A, Arcari P. Analysis of interaction partners for eukaryotic translation elongation factor 1A M-domain by functional proteomics. Biochimie. 93(10):1738-46. Epub 2011 Jun 15. 2011 IF 3.728

225. Franco R, Caraglia M, Facchini G, Abbruzzese A, Botti G. The role of tissue microarray in the era of target-based agents. Expert Rev Anticancer Ther. 11(6):859-69. Review. 2011 IF 2.761

226. Di Domenico M, Santoro A, Ricciardi C, Iaccarino M, Iaccarino S, Freda M, Feola A, Sanguedolce F, Losito S, Pasquali D, Di Spiezo Sardo A, Bifulco G, Nappi C, Bufo P, Guida M, De Rosa G, Abbruzzese A, Caraglia M, Pannone G. Epigenetic fingerprint in endometrial carcinogenesis: the hypothesis of a uterine field cancerization. Cancer Biol Ther. 12(5):447-57. 2011 IF 2.907

227. Barbieri A, Palma G, Rosati A, Giudice A, Falco A, Petrillo A, Petrillo M, Bimonte S, Di Benedetto M, Esposito G, Stiuso P, Abbruzzese A, Caraglia M, Arra C. Role of endothelial nitric oxide synthase (eNOS) in chronic stress-promoted tumour growth. J Cell Mol Med. 16(4):920-6. 2012 IF 4.608

228. Marra M, Salzano G, Leonetti C, Porru M, Franco R, Zappavigna S, Liguori G, Botti G, Chieffi P, Lamberti M, Vitale G, Abbruzzese A, La Rotonda MI, De Rosa G, Caraglia M. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnol Adv. 30(1):302-9. 2012 IF 9.038

229. Caraglia M, Santini D, Bronte G, Rizzo S, Sortino G, Rini GB, Di Fede G, Russo A. Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules. Curr Drug Metab. 12(10):944-55. Review. 2011 IF 3,896

230. Vitale G, Zappavigna S, Marra M, Dicitore A, Meschini S, Condello M, Arancia G, Castiglioni S, Maroni P, Bendinelli P, Piccoletti R, van Koetsveld PM, Cavagnini F, Budillon A, Abbruzzese A, Hofland LJ, Caraglia M. The PPAR- $\gamma$  agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon- $\beta$  treated pancreatic cancer cells. Biotechnol Adv. 30(1):169-84 2012. IF 9.038

231. Caraglia M, Addeo R "Editorial: target therapy in brain tumours and metastases." Curr Cancer Drug Targets. 12(3):185 2012. IF 4.327

232. Caraglia M\*, Marra M, Misso G, Lamberti M, Salzano G, De Rosa G, Abbruzzese A. "Tumour-specific uptake of anti-cancer drugs: the future is here." Curr Drug Metab. Review.13(1):4-21.2012 \* CORRESPONDING AUTHOR IF 3.896
233. De Rosa G, Salzano G, Caraglia M, Abbruzzese A "Nanotechnologies: a strategy to overcome blood-brain barrier." Curr Drug Metab Review. 13(1):61-9. 2012 IF 3.896
234. Sanges C, Scheuermann C, Zahedi RP, Sickmann A, Lamberti A, Migliaccio N, Baljuls A, Marra M, Zappavigna S, Reinders J, Rapp U, Abbruzzese A, Caraglia M, Arcari P. Raf kinases mediate the phosphorylation of eukaryotic translation elongation factor 1A and regulate its stability in eukaryotic cells. Cell Death Dis.1;3:e276. 2012 doi: 10.1038/cddis.2012.16. IF 5.333
235. Galdiero M, Caraglia M. Nanotechnological and biotechnological strategies for drug delivery. Curr Drug Metab. 13(1):2-32012 IF 3.896
236. Ciliberto D, Prati U, Roveda L, Barbieri V, Staropoli N, Abbruzzese A, Caraglia M, Di Maio M, Flotta D, Tassone P, Tagliaferri P Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. Oncol Rep.27(6):1849-56. 2012 IF 1.835
237. Troiani T, Vecchione L, Martinelli E, Capasso A, Costantino S, Ciuffreda LP, Morgillo F, Vitagliano D, D'Aiuto E, De Palma R, Tejpar S, Van Cutsem E, De Lorenzi M, Caraglia M, Berrino L, Ciardiello F. Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. Br J Cancer. 8;106(10):1648-59. 2012 IF 5.042
238. Botta C, Bestoso E, Apollinari S, Cusi MG, Pastina P, Abbruzzese A, Sperlongano P, Misso G, Caraglia M, Tassone P, Tagliaferri P, Correale P. Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients. J Immunother. 35(5):440-7. 2012 IF 3.267
239. Tassone P, Neri P, Burger R, Di Martino MT, Leone E, Amodio N, Caraglia M, Tagliaferri P. Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Curr Cancer Drug Targets.12(7):814-22. 2012 IF 4.327
240. Lamberti M, Porto S, Marra M, Zappavigna S, Grimaldi A, Feola D, Pesce D, Naviglio S, Spina A, Sannolo N, Caraglia M\* 5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress. J Exp Clin Cancer Res. 19;31:60. 2012 \* CORRESPONDING AUTHOR IF 2.15
241. Aquino G, Pannone G, Santoro A, Liguori G, Franco R, Serpico R, Florio G, De Rosa A, Mattoni M, Cozza V, Botti G, Losito S, Longo F, Staibano S, Cuda G, Lo Muzio L, Sbordone C, Bufo P, Grimaldi A, Caraglia M\*, Di Domenico M "pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: A tissue-microarray study with clinic-pathological correlations." Cancer Biol Ther 1;13(11):967-77. 2012 \* CORRESPONDING AUTHOR IF 2.636
242. Liguori G, Cantile M, Cerrone M, La Mantia E, Di Bonito M, Zanconati F, Curcio MP, Aquino G, La Mura A, Giannatiempo R, De Chiara A, Lombardi A, Botti G, D'Antonio A, Caraglia M, Franco R. "Breast MALT lymphomas: A clinicopathological and cytogenetic study of 9 cases." Oncol Rep. 28(4):1211-6. 2012 IF 1.835
243. Addeo R, Sperlongano P, Montella L, Vincenzi B, Carraturo M, Iodice P, Russo P, Parlato C, Salzano A, Cennamo G, Lombardi A, Sperlongano R, Prete SD, Caraglia M. "Protracted low dose of oral vinorelbine and temozolamide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases." Cancer Chemother Pharmacol. 70(4):603-9.2012 IF 2.833
244. Ciliberto D, Botta C, Correale P, Rossi M, Caraglia M, Tassone P, Tagliaferri P. "Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials." Eur J Cancer. 2012 Sep 15. pii: S0959-8049(12)00681-8. doi: 10.1016/j.ejca.2012.08.019. [Epub ahead of print] \* CORRESPONDING AUTHOR IF 5.536
245. Misso G, Porru M, Stoppacciaro A, Castellano M, De Cicco F, Leonetti C, Santini D, Caraglia M\* "Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid." Cancer Biol Ther. 2012 Sep 18;13(14). [Epub ahead of print] \* CORRESPONDING AUTHOR IF 2.636

246. Franco R, Nicoletti G, Lombardi A, Di Domenico M, Botti G, Zito Marino F, Caraglia M. "Current treatment of cutaneous squamous cancer and molecular strategies for its sensitization to new target-based drugs." *Expert Opin Biol Ther.* 2012 Sep 24. [Epub ahead of print] IF 3.505
247. Caraglia M, Dicitore A, Marra M, Castiglioni S, Persani L, Sperlongano P, Tagliaferri P, Abbruzzese A, Vitale G. "Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties." *Protein Pept Lett.* 2012 Sep 13. [Epub ahead of print] IF 1.942
248. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Gallo Cantafio ME, Gullà A, Conforti F, Morelli E, Tomaino V, Rossi M, Negrini M, Ferrarini M, Caraglia M, Shamma MA, Munshi NC, Anderson KC, Neri A, Tagliaferri P, Tassone P. "Synthetic miR-34a mimics as a novel therapeutic agent for Multiple Myeloma: in vitro and in vivo evidence." *Clin Cancer Res.* 2012 Oct 3. [Epub ahead of print] IF 7.742
249. Pelaia G, Gallelli L, Renda T, Fratto D, Falcone D, Caraglia M, Busceti MT, Terracciano R, Varella A, Maselli R, Savino R "Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non-small lung cancer cells." *Cell Prolif.* 2012 Oct 10. doi: 10.1111/j.1365-2184.2012.00846.x. IF 2.521
250. Santini D, Addeo R, Vincenzi B, Calvieri A, Montella L, Silletta M, Caraglia M, Vespasiani U, Picardi A, Del Prete S, Tonini G. "Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma." *Expert Rev Anticancer Ther.* 2012 Oct 24. IF 2.652
251. Amodio N, Leotta M, Bellizzi D, Di Martino MT, D'Aquila P, Lionetti M, Fabiani F, Leone E, Gullà AM, Passarino G, Caraglia M, Negrini M, Neri A, Giordano A, Tagliaferri P, Tassone P. "DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma." *Oncotarget.* 2012 Oct;3(10):1246-58. IF 4.784
252. Buonerba C, Caraglia M, Malgieri S, Perri F, Bosso D, Federico P, Ferro M, Rizzo M, Palmieri G, Di Lorenzo G. Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure? *Expert Opin Biol Ther.* 2013 Feb;13(2):149-51. doi: 10.1517/14712598.2012.756470. Epub 2012 Dec 25. IF 3.505
253. Marra L, Cantile M, Scognamiglio G, Perdonà S, La Mantia E, Cerrone M, Gigantino V, Cillo C, Caraglia M, Pignata S, Facchini G, Botti G, Chieffi S, Chieffi P, Franco R. Deregulation of HOX B13 expression in urinary bladder cancer progression. *Curr Med Chem.* 2013 Feb 1;20(6):833-9. IF 4.859
254. Troiani T, Zappavigna S, Martinelli E, Addeo SR, Stiuso P, Ciardiello F, Caraglia M. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. *Expert Opin Biol Ther.* 2013 Feb;13(2):241-55. doi: 10.1517/14712598.2012.756469. IF 3.505
255. Perna AF, Sepe I, Lanza D, Capasso R, Zappavigna S, Capasso G, Caraglia M, Ingrosso D. Hydrogen sulfide reduces cell adhesion and relevant inflammatory triggering by preventing ADAM17-dependent TNF- $\alpha$  activation. *J Cell Biochem.* 2013 Jan 7. doi: 10.1002/jcb.24495. [Epub ahead of print] IF 2.868
256. Caraglia M, Luongo L, Salzano G, Zappavigna S, Marra M, Guida F, Lusa S, Giordano C, De Novellis V, Rossi F, Abbruzzese Saccardi A, De Rosa G, Maione S. Stealth liposomes encapsulating zoledronic acid: a new opportunity to treat neuropathic pain. *Mol Pharm.* 2013 Mar 4;10(3):1111-8. doi: 10.1021/mp3006215. IF 4.782
257. Spina A, Sorvillo L, Chiosi E, Esposito A, Di Maiolo F, Sapiro L, Caraglia M, Naviglio S. Synergistic cytotoxic effects of inorganic phosphate and chemotherapeutic drugs on human osteosarcoma cells. *Oncol Rep.* 2013 May;29(5):1689-96. doi: 10.3892/or.2013.2306. IF 1.835
258. Di Lorenzo G, Buonerba C, Gaudioso G, Gigantino V, Quarto G, De Domenico R, Caraglia M, Di Trolio R, Ascierto PA, De Placido S, Perdonà S, Franco R. EGFR mutational status in penile cancer. *Expert Opin Ther Targets.* 2013 May;17(5):501-5. doi: 10.1517/14728222.2013.783571. IF 3.505
259. Merlini F, Di Maro S, Munaim Yousif A, Caraglia M, Grieco P. Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures. *J Amino Acids.* 2013;2013:979016. doi: 10.1155/2013/979016 IF 3.248
260. De Rosa G, Misso G, Salzano G, Caraglia M. Bisphosphonates and cancer: what opportunities from nanotechnology? *J Drug Deliv.* 2013;2013:637976. doi: 10.1155/2013/637976 IF 1.02

261. Addeo R, Zappavigna S, Luce A, Facchini S, Caraglia M. Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC. *Expert Opin Drug Saf.* 2013 Apr 8. [Epub ahead of print] IF 3.05
262. Franco R, Rocco G, Marino FZ, Pirozzi G, Normanno N, Morabito A, Sperlongano P, Stiuso P, Luce A, Botti G, Caraglia M. Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment? *Expert Rev Anticancer Ther.* 2013 Apr;13(4):407-20. doi: 10.1586/era.13.18. IF 2.652
263. Dicitore A, Caraglia M, Colao A, Zappavigna S, Mari D, Hofland LJ, Persani L, Vitale G. Combined Treatment With PPAR-γ Agonists In Pancreatic Cancer: A Glimmer Of Hope For Cancer Therapy? *Curr Cancer Drug Targets.* 2013 Mar 25. [Epub ahead of print] IF. 4.327
264. Tesei A, Leonetti C, Di Donato M, Gabucci E, Porru M, Varchi G, Guerrini A, Amadori D, Arienti C, Pignatta S, Paganelli G, Caraglia M, Castoria G, Zoli W. Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models. *PLoS One.* 2013 May 8;8(5):e62657. doi: 10.1371/journal.pone.0062657. IF 4.09
265. Milone MR, Pucci B, Bruzzese F, Carbone C, Piro G, Costantini S, Capone F, Leone A, Di Gennaro E, Caraglia M, Budillon A. Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. *Cell Death Dis.* 2013 May 23;4:e641. doi: 10.1038/cddis.2013.165. IF 6.044
266. Milone MR, Pucci B, Bruzzese F, Carbone C, Piro G, Costantini S, Capone F, Leone A, Di Gennaro E, Caraglia M, Budillon A. Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. *Cell Death Dis.* 2013 May 23;4:e641. doi: 10.1038/cddis.2013.16. IF 6.044
267. Gomez-Monterrey I, Campiglia P, Scognamiglio I, Vanacore D, Dicitore A, Lombardi A, Caraglia M, Novellino E, Stiuso P. DTNQ-Pro, a Mimetic Dipeptide, Sensitizes Human Colon Cancer Cells to 5-Fluorouracil Treatment. *J Amino Acids.* 2013;2013:509056. doi: 10.1155/2013/509056. Epub 2013 Apr 21. IF 3.914.
268. De Rosa G, Caraglia M, Salmaso S, Elbayoumi T. Nanotechnologies in cancer. *J Drug Deliv.* 2013;2013:604293. doi: 10.1155/2013/604293. Epub 2013 May 13. No abstract available.
269. Cucinotto I, Fiorillo L, Gualtieri S, Arbitrio M, Ciliberto D, Staropoli N, Grimaldi A, Luce A, Tassone P, Caraglia M, Tagliaferri P. Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? *J Drug Deliv.* 2013;2013:905091. doi: 10.1155/2013/905091. Epub 2013 May .
270. Misso G, Zappavigna S, Castellano M, De Rosa G, Di Martino MT, Tagliaferri P, Tassone P, Caraglia M. Emerging pathways as individualized therapeutic target of multiple myeloma. *Expert Opin Biol Ther.* 2013 Jun;13 Suppl 1:S95-109. doi: 10.1517/14712598.2013.807338. Epub 2013 Jun 6. IF 3.345
271. Pantano F, Guida FM, Vivaldi C, Vincenzi B, Grande E, Garrote MR, Caraglia M, Silvestris N, Vasile E, Masi G, Falcone A, Tonini G, Santini D. Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. *Cancer Biol Ther.* 2013 Jun;14(6):467-8. doi: 10.4161/cbt.24346. No abstract available. IF 3.287
272. Botta C, Barbieri V, Ciliberto D, Rossi A, Rocco D, Addeo R, Staropoli N, Pastina P, Marvaso G, Martellucci I, Guglielmo A, Pirtoli L, Sperlongano P, Gridelli C, Caraglia M, Tassone P, Tagliaferri P, Correale P. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. *Cancer Biol Ther.* 2013 Jun;14(6):469-75. doi: 10.4161/cbt.24425. IF 3.287
273. Barbieri A, Barretta ML, Rea D, Picone C, Fabozzi O, Palma G, Antonio L, Federico A, Bimonte S, Setola F, De Lutio Di Castelguidone E, Castellano M, D'Errico AG, Caraglia M, Arra C. Intraluminal gel ultrasound and eco-color doppler: new tools for the study of colorectal cancer in mice. *In Vivo.* 2013 Jul-Aug;27(4):443-50. IF 1.219
274. Falco A, Rosati A, Festa M, Basile A, De Marco M, d'Avenia M, Pascale M, Dal Piaz F, Tavano F, Di Mola FF, di Sebastiano P, Berloco PB, Nudo F, Caraglia M, Febbraro A, Barcaroli D, Scarpa A, Pezzilli R, De Laurenzi V, Turco MC. BAG3 is a novel serum biomarker for

- pancreatic adenocarcinomas.  
Am J Gastroenterol. 2013 Jul;108(7):1178-80. doi: 10.1038/ajg.2013.128. IF 7.553
275. Vitale G, Lupoli G, Guerrasi R, Colao A, Dicitore A, Gaudenzi G, Misso G, Castellano M, Addeo R, Facchini G, Del Prete S, Caraglia M  
Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies.  
J Clin Endocrinol Metab. 2013 Oct;98(10):E1567-74. doi: 10.1210/jc.2013-1443IF 6.430.
276. Condello M, Caraglia M, Castellano M, Arancia G, Meschini S.  
Structural and functional alterations of cellular components as revealed by electron microscopy.  
Microsc Res Tech. 2013 Oct;76(10):1057-69. doi: 10.1002/jemt.22266. IF 1.593
277. Iannaccone M, Giuberti G, De Vivo G, Caraglia M, Gentile V Identification of a FXIIIa variant in human neuroblastoma cell lines.  
Int J Biochem Mol Biol. 2013 Jul 29;4(2):102-7. IF 4.152
278. Stiuso P, Caraglia M, De Rosa G, Giordano A. Bioactive peptides in cancer: therapeutic use and delivery strategies.  
J Amino Acids. 2013;2013:568953. doi: 10.1155/2013/568953 IF 3.914.
279. Palma G, Barbieri A, Bimonte S, Palla M, Zappavigna S, Caraglia M, Ascierto PA, Ciliberto G, Arra C. Interleukin 18: Friend or foe in cancer.  
Biochim Biophys Acta. 2013 Oct 8;1836(2):296-303. doi: 10.1016/j.bbcan.2013.09.001 IF 3.848
280. Nicoletti R, Ferranti P, Caira S, Misso G, Castellano M, Di Lorenzo G, Caraglia M.  
Myrtucommulone production by a strain of Neofusicoccum australe endophytic in myrtle (Myrtus communis).  
World J Microbiol Biotechnol. 2014 Mar;30(3):1047-52. doi: 10.1007/s11274-013-1523-x. IF 1.262
281. De Maria S, Scognamiglio I, Lombardi A, Amodio N, Caraglia M, Cartenì M, Ravagnan G, Stiuso P Polydatin, a natural precursor of resveratrol, induces cell cycle arrest and differentiation of human colorectal Caco2 cell.  
J Transl Med. 2013 Oct 20;11(1):264. IF 3.46
282. Bruzzese F, Pucci B, Milone MR, Ciardiello C, Franco R, Chianese MI, Rocco M, Di Gennaro E, Leone A, Luciano A, Arra C, Santini D, Caraglia M, Budillon A. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.  
Cell Death Dis. 2013 Oct 24;4:e878. doi: 10.1038/cddis.2013.406. IF 6.044
283. Grimaldi A, Balestrieri ML, D'Onofrio N, Di Domenico G, Nocera C, Lamberti M, Tonini G, Zoccoli A, Santini D, Caraglia M, Pantano F. The synergistic effect of everolimus and chloroquine on endothelial cell number reduction is paralleled by increased apoptosis and reduced autophagy occurrence.  
PLoS One. 2013 Nov 11;8(11):e79658. doi: 10.1371/journal.pone.0079658. eCollection 2013.
284. Federico A, Zappavigna S, Romano M, Grieco P, Luce A, Marra M, Gravina AG, Stiuso P, D'Armiento FP, Vitale G, Tuccillo C, Novellino E, Loguerio C, Caraglia M. Urotensin-II receptor is over-expressed in colon cancer cell lines and in colon carcinoma in humans.  
Eur J Clin Invest. 2013 Dec 30. doi: 10.1111/eci.12231.
285. Del Prete S, Cinieri S, Lorusso V, Maiorino L, Pizza C, Pisano A, Montesarchio V, Leo L, Savastano C, Pistolese G, Bianco M, Mabilia R, Tonachella R, Febbraro A, Manzione L, Palazzo S, Filippelli G, Vincenzi B, Barbato E, Cennamo G, Riccardi F, Misso G, Caraglia M, Addeo R. Impact of anemia management with EPO on psychologic distress in cancer patients: results of a multicenter patient survey.  
Future Oncol. 2014 Jan;10(1):69-78. doi: 10.2217/fon.13.161.
286. Correale P, Botta C, Rotundo MS, Guglielmo A, Conca R, Licchetta A, Pastina P, Bestoso E, Ciliberto D, Cusi MG, Fioravanti A, Guidelli GM, Bianco MT, Misso G, Martino E, Caraglia M, Tassone P, Mini E, Mantovani G, Ridolfi R, Pirtoli L, Tagliaferri P. Gemcitabine, oxaliplatin, levofofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial.  
J Immunother. 2014 Jan;37(1):26-35. doi: 10.1097/CJI.0000000000000004.
287. Dicitore A, Caraglia M, Gaudenzi G, Manfredi G, Amato B, Mari D, Persani L, Arra C, Vitale G. Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): At the cross-road of pancreatic cancer cell proliferation.  
Biochim Biophys Acta. 2014 Jan;1845(1):42-52. doi: 10.1016/j.bbcan.2013.11.003.
288. Pannone G, Santoro A, Feola A, Bufo P, Papagerakis P, Lo Muzio L, Staibano S, Ionna F, Longo F, Franco R, Aquino G, Contaldo M, De Maria S, Serpico R, De Rosa A, Rubini C, Papagerakis S, Giovane A, Tombolini V, Giordano A, Caraglia M, Di Domenico M. The Role Of E-Cadherin Down-Regulation In Oral Cancer: Cdh1 Gene Expression And Epigenetic Blockage.  
Curr Cancer Drug Targets. 2013 Nov 25. [Epub ahead of print]

289. D'Angelo V, Pecoraro G, Indolfi P, Iannotta A, Donofrio V, Errico ME, Indolfi C, Ramaglia M, Lombardi A, Di Martino M, Gigantino V, Baldi A, Caraglia M, De Luca A, Casale F. Expression and localization of serine protease Htra1 in neuroblastoma: correlation with cellular differentiation grade. *J Neurooncol.* 2014 Apr;117(2):287-94. doi: 10.1007/s11060-014-1387-4. Epub 2014 Feb 4.
290. Di Martino MT, Campani V, Misso G, Gallo Cantafio ME, Gullà A, Foresta U, Guzzi PH, Castellano M, Grimaldi A, Gigantino V, Franco R, Lusa S, Cannataro M, Tagliaferri P, De Rosa G, Tassone P, Caraglia M In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. *PLoS One.* 2014 Feb 27;9(2):e90005. doi: 10.1371/journal.pone.0090005. eCollection 2014.
291. Pizzi C, Arpino G, Acampora G, Aiello N, DE Rosa A, Diaferia I, DI Nunzio A, Fragna G, Franco A, Russo M, Sansone F, Scarpati C, Spinuso A, Arpino G, Luce A, Tommasielli G, Caraglia M, DE Placido S. Cancer prevalence in the city of Naples: Contribution of the GP database analyses to the cancer registries network. *Mol Clin Oncol.* 2013 Jul;1(4):726-732. Epub 2013 Apr 4.
292. Marvao G, Barone A, Amadio N, Raimondi L, Agosti V, Altomare E, Scotti V, Lombardi A, Bianco R, Bianco C, Caraglia M, Tassone P, Tagliaferri P. Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro. *Cancer Biol Ther.* 2014 Mar 21;15(6). [Epub ahead of print]
293. Staropoli N, Ciliberto D, Botta C, Fiorillo L, Grimaldi A, Lama S, Caraglia M, Salvino A, Tassone P, Tagliaferri P Pegylated liposomal doxorubicin in the management of ovarian cancer: A systematic review and metaanalysis of randomized trials. *Cancer Biol Ther.* 2014 Mar 21;15(6). [Epub ahead of print]
294. Scognamiglio I, Di Martino MT, Campani V, Virgilio A, Galeone A, Gullà A, Gallo Cantafio ME, Misso G, Tagliaferri P, Tassone P, Caraglia M, De Rosa G. Transferrin-Conjugated SNALPs Encapsulating 2'-O-Methylated miR-34a for the Treatment of Multiple Myeloma. *Biomed Res Int.* 2014;2014:217365. doi: 10.1155/2014/217365. Epub 2014 Feb 13.
295. D'Onofrio N, Caraglia M, Grimaldi A, Marfella R, Servillo L, Paolisso G, Balestrieri ML. Vascular -homing peptides for targeted drug delivery and molecular imaging: Meeting the clinical challenges. *Biochim Biophys Acta.* 2014 Apr 1;1846(1):1-12. doi: 10.1016/j.bbcan.2014.03.004. [Epub ahead of print] Review.
296. Lamberti M, Porto S, Zappavigna S, Addeo E, Marra M, Miraglia N, Sannolo N, Vanacore D, Stiuso P, Caraglia M. A mechanistic study on the cardiotoxicity of 5-fluorouracil in vitro and clinical and occupational perspectives. *Toxicol Lett.* 2014 Apr 1. pii: S0378-4274(14)00140-4. doi: 10.1016/j.toxlet.2014.03.018
297. Lamberti M, Zappavigna S, Sannolo N, Caraglia M. Advantages and risks of nanotechnologies in cancer patients and occupationally exposed workers. *Expert Opin Drug Deliv.* 2014 Jul;11(7):1087-101. doi: 10.1517/17425247.2014.913568
298. Rossi M, Rotblat B, Ansell K, Amelio I, Caraglia M, Misso G, Bernassola F, Cavasotto CN, Knight RA, Ciechanover A, Melino G. High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antidepressant drugs as regulators of autophagy. *Cell Death Dis.* 2014 May 1;5:e1203. doi: 10.1038/cddis.2014.113.
299. Addeo R, Zappavigna S, Parlato C, Caraglia M Erlotinib: early clinical development in brain cancer. *Expert Opin Investig Drugs.* 2014 Jul;23(7):1027-37. doi:10.1517/13543784.2014.918950..
300. Galdiero S, Falanga A, Vitiello M, Grieco P, Caraglia M, Morelli G, Galdiero M. Exploitation of viral properties for intracellular delivery. *J Pept Sci.* 2014 Jul;20(7):468-78. doi: 10.1002/psc.2649.
301. Franco R, Zappavigna S, Gigantino V, Luce A, Cantile M, Cerrone M, Facchini G, Perdonà S, Pignata S, Di Lorenzo G, Chieffi S, Vitale G, De Sio M, Sgambato A, Botti G, Yousif AM, Novellino E, Grieco P, Caraglia M. Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion. *J Exp Clin Cancer Res.* 2014 Jun 3;33:48. doi: 10.1186/1756-9966-33-48.
302. Mesolella M, Luce A, Marino A, Caraglia M, Ricciardiello F, Iengo M. Treatment of c-kit positive adenoid cystic carcinoma of the tongue: A case report. *Oncol Lett.* 2014 Jul;8(1):309-312. Epub 2014 Apr 16.
303. Rizzo A, Misso G, Bevilacqua N, Donnarumma G, Lombardi A, Galdiero M, Caraglia M. Zoledronic acid affects the cytotoxic effects of Chlamydia pneumoniae and the modulation of cytokine production in human osteosarcoma cells. *Int Immunopharmacol.* 2014 Sep;22(1):66-72. doi: 10.1016/j.intimp.2014.06.019.

304. Stiuso P, Scognamiglio I, Murolo M, Ferranti P, De Simone C, Rizzo MR, Tuccillo C, Caraglia M, Loguerio C, Federico A. Serum oxidative stress markers and lipidomic profile to detect NASH patients responsive to an antioxidant treatment: a pilot study. *Oxid Med Cell Longev.* 2014;169216. doi: 10.1155/2014/169216.
305. Ieranò C, Santagata S, Napolitano M, Guardia F, Grimaldi A, Antignani E, Botti G, Consales C, Riccio A, Nanayakkara M, Barone MV, Caraglia M, Scala S. CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells. *Cell Death Dis.* 2014 Jul 3;5:e1310. doi: 10.1038/cddis.2014.269.
306. Manfredi GI, Dicitore A, Gaudenzi G, Caraglia M, Persani L, Vitale G. PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy. *Endocrine.* 2014 Aug 13. [Epub ahead of print]
307. Monda M, Messina G, Scognamiglio I, Lombardi A, Martin GA, Sperlongano P, Porcelli M, Caraglia M, Stiuso P. Short-term diet and moderate exercise in young overweight men modulate cardiocyte and hepatocarcinoma survival by oxidative stress. *Oxid Med Cell Longev.* 2014;131024. doi: 10.1155/2014/131024.
308. Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P, Tassone P, Caraglia M. Mir-34: a new weapon against cancer? *Mol Ther Nucleic Acids.* 2014 Sep 23;3:e194. doi: 10.1038/mtna.2014.47. Review.
309. Caraglia M, Alaia C, Porcelli M. From Protein Synthesis to Molecular Biology: The Appealing Tale of eIF-5A. *Mol Ther Nucleic Acids.* 2014 Oct 7;3:e199. doi: 10.1038/mtna.2014.53. No abstract available
310. Vasca V, Vasca E, Freiman P, Marian D, Luce A, Mesolella M, Caraglia M, Ricciardiello F, Duminica T. Keratin 5 expression in squamouscellular carcinoma of the head and neck. *Oncol Lett.* 2014 Dec;8(6):2501-2504. Epub 2014 Oct 9.
311. Porru M, Zappavigna S, Salzano G, Luce A, Stoppacciaro A, Balestrieri ML, Artuso S, Lusa S, De Rosa G, Leonetti C, Caraglia M. Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid. *Oncotarget.* 2014 Nov 15;5(21):10446-59.
312. Schiraldi C, Zappavigna S, D' Agostino A, Porto S, Gaito O, Lusa S, Lamberti M, De Rosa M, De Rosa G, Caraglia M. Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique. *Cancer Biol Ther.* 2014;15(11):1524-32. doi: 10.4161/15384047.2014.955989.
313. Franco R, Collina F, Di Bonito M, Botti G, Montanaro D, Di Maio L, Vincenzi B, Landi G, D'Aiuto M, Caraglia M, Baldi A. HtrA1 loss is related to aggressive behavior parameters in sentinel node positive breast cancer. *Histol Histopathol.* 2014 Dec 22.
314. Ilisso CP, Castellano M, Zappavigna S, Lombardi A, Vitale G, Dicitore A, Cacciapuoti G, Caraglia M, Porcelli M. The methyl donor S-adenosylmethionine potentiates doxorubicin effects on apoptosis of hormone-dependent breast cancer cell lines. *Endocrine.* 2015 Jan 11.
315. De Rosa A, Zappavigna S, Villa MR, Improta S, Cesario E, Mastrullo L, Caraglia M, Stiuso P. Prognostic role of translocator protein and oxidative stress markers in chronic lymphocytic leukemia patients treated with bendamustine plus rituximab. *Oncol Lett.* 2015 Mar;9(3):1327-1332. Epub 2014 Dec 19.
316. Lamberti M, Porto S, Zappavigna S, Stiuso P, Tirino V, Desiderio V, Mele L, Caraglia M. Levofofene modulates apoptosis induced by 5-fluorouracil through autophagy inhibition: Clinical and occupational implications. *Int J Oncol.* 2015 Feb 24. doi: 10.3892/ijo.2015.2904.
317. Stiuso P, Potenza N, Lombardi A, Ferrandino I, Monaco A, Zappavigna S, Vanacore D, Mosca N, Castiello F, Porto S, Addeo R, Prete SD, De Vita F, Russo A, Caraglia M. MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib. *Mol Ther Nucleic Acids.* 2015 Mar 17;4:e233. doi: 10.1038/mtna.2015.8.
318. Lamberti M, Pedata P, Sannolo N, Porto S, De Rosa A, Caraglia M.

Carbon nanotubes: Properties, biomedical applications, advantages and risks in patients and occupationally-exposed workers. *Int J Immunopathol Pharmacol.* 2015 Mar;28(1):4-13. doi: 10.1177/0394632015572559.

319. Dicitore A, Grassi ES, Caraglia M, Borghi MO, Gaudenzi G, Hofland LJ, Persani L, Vitale G.

The cAMP analogs have potent anti-proliferative effects on medullary thyroid cancer cell lines. *Endocrine.* 2016 Jan;51(1):101-12. doi: 10.1007/s12020-015-0597-7.

320. Grimaldi A, Santini D, Zappavigna S, Lombardi A, Misso G, Boccellino M, Desiderio V, Vitiello PP, Di Lorenzo G, Zoccoli A, Pantano F, Caraglia M. Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells. *Cancer Biol Ther.* 2015;16(4):567-79. doi: 10.1080/15384047.2015.1018494. Epub 2015 Apr 11.

321. Pace MC, Passavanti MB, Aurilio C, Sansone P, Aurilio R, DE Maria S, Lama S, Federico A, Ravagnan G, Caraglia M, Stiuso P. Polydatin administration improves serum biochemical parameters and oxidative stress markers during chronic alcoholism: a pilot study. *In Vivo.* 2015 May-Jun;29(3):405-8.

322. Del Pup L, Mantovani A, Luce A, Cavaliere C, Facchini G, Di Francia R, Caraglia M, Berretta M. Endocrine disruptors and female cancer: Informing the patients (Review). *Oncol Rep.* 2015 Jul;34(1):3-11. doi: 10.3892/or.2015.3997. Epub 2015 May 20. Review.

323. Boccellino M, Alaia C, Misso G, Cossu AM, Facchini G, Piscitelli R, Quagliuolo L, Caraglia M. Gene interference strategies as a new tool for the treatment of prostate cancer. *Endocrine.* 2015 Aug;49(3):588-605. doi: 10.1007/s12020-015-0629-3. Epub 2015 Jun 7.

324. Barbieri A, Bimonte S, Palma G, Luciano A, Rea D, Giudice A, Scognamiglio G, La Mantia E, Franco R, Perdonà S, De Cobelli O, Ferro M, Zappavigna S, Stiuso P, Caraglia M, Arra C. The stress hormone norepinephrine increases migration of prostate cancer cells in vitro and in vivo. *Int J Oncol.* 2015 Aug;47(2):527-34. doi: 10.3892/ijo.2015.3038. Epub 2015 Jun 8.

325. Ciliberto D, Staropoli N, Caglioti F, Gualtieri S, Fiorillo L, Chiellino S, De Angelis AM, Mendicino F, Botta C, Caraglia M, Tassone P, Tagliaferri P. A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? *Cancer Biol Ther.* 2015;16(8):1148-59. doi: 10.1080/15384047.2015.1056415. Epub 2015 Jun 10.

326. La Regina G, Bai R, Coluccia A, Famiglini V, Pelliccia S, Passacantilli S, Mazzoccoli C, Ruggieri V, Verrico A, Miele A, Monti L, Nalli M, Alfonsi R, Di Marcotullio L, Gulino A, Ricci B, Soriani A, Santoni A, Caraglia M, Porto S, Da Pozzo E, Martini C, Brancale A, Marinelli L, Novellino E, Vultaggio S, Varasi M, Mercurio C, Bigogno C, Dondio G, Hamel E, Lavia P, Silvestri R. New Indole Tubulin Assembly Inhibitors Cause Stable Arrest of Mitotic Progression, Enhanced Stimulation of Natural Killer Cell Cytotoxic Activity, and Repression of Hedgehog-Dependent Cancer. *J Med Chem.* 2015 Aug 13;58(15):5789-807. doi: 10.1021/acs.jmedchem.5b00310. Epub 2015 Jul 20.

327. Liguori G, Cantile M, Collina F, Marra L, DE Chiara A, Franco R, Caraglia M, Botti G, D'Andrea M, Nicoletti GF. Atypical amplification of chromosome region 22q12 in melanoma: A case report. *Oncol Lett.* 2015 Jul;10(1):349-353. Epub 2015 Apr 27.

328. Lamberti M, Capasso R, Lombardi A, Di Domenico M, Fiorelli A, Feola A, Perna AF, Santini M, Caraglia M, Ingrosso D. Two Different Serum MiRNA Signatures Correlate with the Clinical Outcome and Histological Subtype in Pleural Malignant Mesothelioma Patients. *PLoS One.* 2015 Aug 11;10(8):e0135331. doi: 10.1371/journal.pone.0135331. eCollection 2015.

329. D'Angelo V, Iannotta A, Ramaglia M, Lombardi A, Zarone MR, Desiderio V, Affinita MC, Pecoraro G, Di Martino M, Indolfi P, Casale F, Caraglia M. EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches. *J Exp Clin Cancer Res.* 2015 Aug 14;34:83. doi: 10.1186/s13046-015-0191-0.

330. Pepe P, Castellano M, Alfano S, Della Pepa ME, Tirino V, Piemonte M, Desiderio V, Zappavigna S, Galdiero M, Caraglia M, Cringoli G, Rinaldi L, Galdiero M. Dicrocoelium dendriticum induces autophagic vacuoles accumulation in human hepatocarcinoma cells. *Vet Parasitol.* 2015 Sep 15;212(3-4):175-80. doi: 10.1016/j.vetpar.2015.07.039. Epub 2015 Aug 6.

331. Federico A, Dallio M, Di Fabio G, Zarrelli A, Zappavigna S, Stiuso P, Tuccillo C, Caraglia M, Loguercio C. Silybin-Phosphatidylcholine Complex Protects Human Gastric and Liver Cells from Oxidative Stress. *In Vivo.* 2015 Sep-Oct;29(5):569-75.
332. Kopecka J, Porto S, Lusa S, Gazzano E, Salzano G, Giordano A, Desiderio V, Ghigo D, Caraglia M, De Rosa G, Riganti C Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells. *Oncotarget.* 2015 Oct 13;6(31):31461-78. doi: 10.18632/oncotarget.5058.
333. De Cobelli O, Buonerba C, Terracciano D, Bottero D, Lucarelli G, Bove P, Altieri V, Coman I, Perdonà S, Facchini G, Berretta M, Di Lorenzo G, Grieco P, Novellino E, Franco R, Caraglia M, Manini C, Mirone V, De Placido S, Sonpavde G, Ferro M. Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. *Future Oncol.* 2015 Nov;11(22):3091-8. doi: 10.2217/fon.15.249. Epub 2015 Sep 18.
334. Ferro M, De Cobelli O, Buonerba C, Di Lorenzo G, Capece M, Bruzzese D, Autorino R, Bottero D, Cioffi A, Matei DV, Caraglia M et al. Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience. *Medicine (Baltimore).* 2015 Oct;94(42):e1861. doi: 10.1097/MD.0000000000001861.
335. Perillo E, Porto S, Falanga A, Zappavigna S, Stiuso P, Tirino V, Desiderio V, Papaccio G, Galdiero M, Giordano A, Galdiero S, Caraglia M. Liposome armed with herpes virus-derived gH625 peptide to overcome doxorubicin resistance in lung adenocarcinoma cell lines. *Oncotarget.* 2016 Jan 26;7(4):4077-92. doi: 10.18632/oncotarget.6013.
336. Ricciardiello F, Fattore L, Liguori ME, Oliva F, Luce A, Abate T, Caraglia M, Pianese A, Raucci AF. Temporal bone meningioma involving the middle ear: A case report. *Oncol Lett.* 2015 Oct;10(4):2249-2252. Epub 2015 Jul 20.
337. Klionsky DJ et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy.* 2016 Jan 2;12(1):1-222. No abstract available.
338. Kopecka J, Porto S, Lusa S, Gazzano E, Salzano G, Pinzòn-Daza ML, Giordano A, Desiderio V, Ghigo D, De Rosa G, Caraglia M, Riganti C. Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors. *Oncotarget.* 2016 Mar 9. doi: 10.18632/oncotarget.8012.
339. Ieranò C, Portella L, Lusa S, Salzano G, D'Alterio C, Napolitano M, Buoncervello M, Macchia D, Spada M, Barbieri A, Luciano A, Barone MV, Gabriele L, Caraglia M, Arra C, De Rosa G, Scala S. CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis. *Nanoscale.* 2016 Mar 31;8(14):7562-71. doi: 10.1039/c5nr06335c.
340. Amadio N, Stamato MA, Gullà AM, Morelli E, Romeo E, Raimondi L, Pitari MR, Ferrandino I, Misso G, Caraglia M, Perrotta I, Neri A, Fulciniti M, Rolfo C, Anderson KC, Munshi NC, Tagliaferri P, Tassone P. Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma. *Mol Cancer Ther.* 2016 Mar 28. pii: molcanther.0985.2015.
341. Beretta M, Caraglia M, Martellotta F, Zappavigna S, Lombardi A, Fierro C, Atripaldi L, Muto T, Valente D, De Paoli P, Tirelli U, Di Francia R. Drug-Drug Interactions Based on Pharmacogenetic Profile between Highly Active Antiretroviral Therapy and Antiblastic Chemotherapy in Cancer Patients with HIV Infection. *Front Pharmacol.* 2016 Mar 30;7:71. doi: 10.3389/fphar.2016.00071. eCollection 2016. Review.
342. Mesolella M, Iorio B, Misso G, Luce A, Cimmino M, Iengo M, Landi M, Sperlongano P, Caraglia M, Ricciardiello F. Role of perineural invasion as a prognostic factor in laryngeal cancer. *Oncol Lett.* 2016 Apr;11(4):2595-2598. Epub 2016 Feb 24.
343. Zappavigna S, Misso G, Falanga A, Perillo E, Novellino E, Galdiero M, Grieco P, Caraglia M, Galdiero S. Nanocarriers Conjugated with Cell Penetrating Peptides: New Trojan Horses by Modern Ulysses. *Curr Pharm Biotechnol.* 2016 Apr 15
344. Stiuso P, Bagarolo ML, Ilisso CP, Vanacore D, Martino E, Caraglia M, Porcelli M, Cacciapuoti G. Protective Effect of Tyrosol and S-Adenosylmethionine against Ethanol-Induced Oxidative Stress of HepG2 Cells Involves Sirtuin 1, P53 and

Erk1/2 Signaling. *Int J Mol Sci.* 2016 Apr 26;17(5). pii: E622. doi: 10.3390/ijms17050622.

345. Amodio N, Stamato MA, Gullà AM, Morelli E, Romeo E, Raimondi L, Pitari MR, Ferrandino I, Misso G, Caraglia M, Perrotta I, Neri A, Fulciniti M, Rolfo C, Anderson KC, Munshi NC, Tagliaferri P, Tassone P. Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. *Mol Cancer Ther.* 2016 Jun;15(6):1364-75. doi: 10.1158/1535-7163.MCT-15-0985-T.

346. Misso G, Zarone MR, Grimaldi A, Di Martino MT, Lombardi A, Kawasaki H, Stiuso P, Tassone P, Tagliaferri P, Caraglia M. Non Coding RNAs: a new avenue for the self-tailoring of blood cancer treatment. *Curr Drug Targets.* 2017;18(1):35-55.

347. Salzano G, Zappavigna S, Luce A, D'Onofrio N, Balestrieri ML, Grimaldi A, Lusa S, Ingrosso D, Artuso S, Porru M, Leonetti C, Caraglia M, De Rosa G. Transferrin-Targeted Nanoparticles Containing Zoledronic Acid as a Potential Tool to Inhibit Glioblastoma Growth. *J Biomed Nanotechnol.* 2016 Apr;12(4):811-30.

348. Federico A, Zappavigna S, Dallio M, Misso G, Merlino F, Loguercio C, Novellino E, Grieco P, Caraglia M. Urotensin-II receptor: a double identity receptor involved in vasoconstriction and in the development of digestive tract cancers and other tumors. *Curr Cancer Drug Targets.* 2017;17(2):109-121.

349. Del Pup L, Mantovani A, Cavaliere C, Facchini G, Luce A, Sperlongano P, Caraglia M, Beretta M. Carcinogenetic mechanisms of endocrine disruptors in female cancers (Review). *Oncol Rep.* 2016 Aug;36(2):603-12. doi: 10.3892/or.2016.4886.

350. Addeo R, Caraglia M, Iuliano G. Pembrolizumab: the value of PDL1 biomarker in head and neck cancer. *Expert Opin Biol Ther.* 2016 Sep;16(9):1075-8. doi: 10.1080/14712598.2016.1211635.

351. Botta C, Misso G, Martino EC, Pirtoli L, Cusi MG, Tassone P, Tagliaferri P, Caraglia M, Correale P. The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response. *Cell Death Dis.* 2016 Jul 21;7:e2299. doi: 10.1038/cddis.2016.211.

352. Di Lorenzo G, De Placido S, Pagliuca M, Ferro M, Lucarelli G, Rossetti S, Bosso D, Puglia L, Pignataro P, Ascione I, De Cobelli O, Caraglia M, Aieta M, Terracciano D, Facchini G, Buonarba C, Sonpavde G. The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. *Expert Opin Biol Ther.* 2016 Nov;16(11):1387-1401.

353. Ramaglia M, D'Angelo V, Iannotta A, Di Pinto D, Pota E, Affinita MC, Donofrio V, Errico ME, Lombardi A, Indolfi C, Casale F, Caraglia M. High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas. *Cancer Cell Int.* 2016 Jul 28;16:59. doi: 0.1186/s12935-016-0338-x.

354. Gagliardi A, Carbone C, Russo A, Cuccurullo R, Lucania A, Cioppa PD, Misso G, Caraglia M, Tommasino C, Mastrullo L. Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports. *Oncol Lett.* 2016 Oct;12(4):2363-2370.

355. Boccellino M, Quagliuolo L, Alaia C, Grimaldi A, Addeo R, Nicoletti GF, Kast RE, Caraglia M. The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity. *Curr Med Res Opin.* 2016 Nov;32(11):1839-1848.

356. Martino EC, Misso G, Pastina P, Costantini S, Vanni F, Gandolfo C, Botta C, Capone F, Lombardi A, Pirtoli L, Tassone P, Olivieri C, Tagliaferri P, Cusi MG, Caraglia M, Correale P. Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. *Cell Death Discov.* 2016 Oct 3;2:16025.

357. Carbone C, Di Gennaro E, Piro G, Milone MR, Pucci B, Caraglia M, Budillon A. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat. *Amino Acids.* 2016 Oct 19.

358. Zappavigna S, Scuotto M, Cossu AM, Ingrosso D, De Rosa M, Schiraldi C, Filosa R, Caraglia M. The 1,4 benzoquinone-featured 5-lipoxygenase inhibitor RF-Id induces apoptotic death through downregulation of IAPs in human glioblastoma cells. *J Exp Clin Cancer Res.* 2016 Oct 22;35(1):167.

359. Romano FJ, Rossetti S, Conteduca V, Schepisi G, Cavaliere C, Di Franco R, La Mantia E, Castaldo L, Nocerino F, Ametrano G, Cappuccio F, Malzone G, Montanari M, Vanacore D, Quagliariello V, Piscitelli R, Pepe MF, Beretta M, D'Aniello C, Perdonà S, Muto P, Botti G, Ciliberto G, Veneziani BM, De Falco F, Maiolino P, **Caraglia M**, Montella M, De Giorgi U, Facchini G. Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review. *Oncotarget.* 2016 Dec 20;7(51):85641-85649. doi: 10.18632/oncotarget.13063. IF 5.5

360. Simental-Mendía LE, **Caraglia M**, Majeed M, Sahebkar A. Impact of curcumin on the regulation of microRNAs in colorectal cancer. *Expert Rev Gastroenterol Hepatol.* 2017 Feb;11(2):99-101. doi: 10.1080/17474124.2017.1268528. IF 2.8

361. Potenza N, Mosca N, Zappavigna S, Castiello F, Panella M, Ferri C, Vanacore D, Giordano A, Stiuso P, **Caraglia M**, Russo A. MicroRNA-125a-5p Is a Downstream Effector of Sorafenib in Its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells. *J Cell Physiol.* 2017 Jul;232(7):1907-1913. IF 4.15

362. Cave DD, Desiderio V, Mosca L, Paola Iliiso C, Mele L, Caraglia M, Cacciapuoti G, Porcelli M.

S-ADENOSYLMETHIONINE-MEDIATED APOPTOSIS IS POTENTIATED BY AUTOPHAGY INHIBITION INDUCED BY CHLOROQUINE IN HUMAN BREAST CANCER CELLS.

J Cell Physiol. 2017 May 18. doi: 10.1002/jcp.26015. [Epub ahead of print]

363. Correale P, Botta C, Ciliberto D, Pastina P, Ingariola R, Zappavigna S, Tassone P, Pirtoli L, Caraglia M, Tagliaferri P.

Immunotherapy of colorectal cancer: new perspectives after a long path.

Immunotherapy. 2016 Nov;8(11):1281-1292.

364. Berretta M, Di Francia R, De Divitis C, Nasti G, Canzonieri V, Caraglia M, Facchini G, Tirelli U.

The Role of Target Therapy in the Treatment of Gastrointestinal Non Colorectal Cancers: Clinical Impact and Cost Consideration. Curr Cancer Drug Targets. 2017 Feb 8. doi: 10.2174/1568009617666170208162058.

365. Facchini G, Perri F, Misso G, D'Aniello C, Scarpati GD, Rossetti S, Pepa CD, Pisconti S, Unteregger G, Cossu A, Caraglia M, Berretta M, Cavaliere C.

Optimal Management of Prostate Cancer Based on its Natural Clinical History.

Curr Cancer Drug Targets. 2017 Feb 8. doi: 10.2174/1568009617666170209093101.

366. D'Aniello C, Perri F, Scarpati GD, Pepa CD, Pisconti S, Montesarchio V, Wernert N, Zarone MR, Caraglia M, Facchini G, Berretta M, Cavaliere C.

MELANOMA ADJUVANT TREATMENT: current insight and clinical features.

Curr Cancer Drug Targets. 2017 Feb 8. doi: 10.2174/1568009617666170208163714.

367. Zappavigna S, Lombardi A, Misso G, Grimaldi A, Caraglia M.

Measurement of Autophagy by Flow Cytometry.

Methods Mol Biol. 2017;1553:209-216.

368. Dicitore A, Grassi ES, Borghi MO, Gelmini G, Cantone MC, Gaudenzi G, Persani L, Caraglia M, Vitale G.

Antitumor activity of interferon- $\beta$ 1a in hormone refractory prostate cancer with neuroendocrine differentiation.

J Endocrinol Invest. 2017 Jul;40(7):761-770.

369. Shahabipour F, Caraglia M, Majeed M, Derosa G, Maffioli P, Sahebkar A.

Naturally occurring anti-cancer agents targeting EZH2.

Cancer Lett. 2017 Aug 1;400:325-335.

370. Irace C, Misso G, Capuozzo A, Piccolo M, Riccardi C, Luchini A, Caraglia M, Paduano L, Montesarchio D, Santamaria R.

Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action.

Sci Rep. 2017 Mar 28;7:45236.

371. Quagliariello V, Rossetti S, Cavaliere C, Di Palo R, Lamantia E, Castaldo L, Nocerino F, Ametrano G, Cappuccio F, Malzone G, Montanari M, Vanacore D, Romano FJ, Piscitelli R, Iovane G, Pepe MF, Berretta M, D'Aniello C, Perdonà S, Muto P, Botti G, Ciliberto G, Veneziani BM, De Falco F, Maiolino P, Caraglia M, Montella M, Iaffaioli RV, Facchini G.

Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences.

Oncotarget. 2017 May 2;8(18):30606-30616. doi: 10.18632/oncotarget.16725.

372. Lombardi A, Grimaldi A, Zappavigna S, Misso G, Caraglia M.

Hepatocarcinoma: genetic and epigenetic features.

Minerva Gastroenterol Dietol. 2017 Apr 11. doi: 10.23736/S1121-421X.17.02408-4. [Epub ahead of print]

373. Vanacore D, Boccellino M, Rossetti S, Cavaliere C, D'Aniello C, Di Franco R, Romano FJ, Montanari M, La Mantia E, Piscitelli R, Nocerino F, Cappuccio F, Grimaldi G, Izzo A, Castaldo L, Pepe MF, Malzone MG, Iovane G, Ametrano G, Stiuso P, Quagliuolo L, Barberio D, Perdonà S, Muto P, Montella M, Maiolino P, Veneziani BM, Botti G, Caraglia M, Facchini G. Micromas in prostate cancer: an overview. Oncotarget. 2017 Jul 25;8(30):50240-50251.

374. Vitale G, Dicitore A, Pepe D, Gentilini D, Grassi ES, Borghi MO, Gelmini G, Cantone MC, Gaudenzi G, Misso G, Di Blasio AM, Hofland LJ, Caraglia M, Persani L.

Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines.

Mol Oncol. 2017 Apr 28. doi: 10.1002/1878-0261.12070.

375. Lo Re O, Panebianco C, Porto S, Cervi C, Rappa F, Di Biase S, Caraglia M, Pazienza V, Vinciguerra M.

Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.

J Cell Physiol. 2017 May 4. doi: 10.1002/jcp.25987.

376. Borghese C, Casagrande N, Pivetta E, Colombatti A, Boccellino M, Amler E, Normanno N, Caraglia M, De Rosa G, Aldinucci D.

Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells. *Oncotarget.* 2017 Jun 27;8(26):42926-42938.

377. Momtazi-Borojeni AA, Abdollahi E, Ghasemi F, Caraglia M, Sahebkar A. The novel role of pyrvinium in cancer therapy. *J Cell Physiol.* 2017 May 13. doi: 10.1002/jcp.26006. [Epub ahead of print] Review. PMID: 28500633

378. Saberi-Karimian M, Katsiki N, Caraglia M, Boccellino M, Majeed M, Sahebkar A. Vascular endothelial growth factor: an important molecular target of curcumin. *Crit Rev Food Sci Nutr.* 2017 Aug 30:0. doi: 10.1080/10408398.2017.1366892. [Epub ahead of print]

379. Ottaiano A, Nasti G, Cassata A, De Stefano A, Caraglia M, Avallone A. FOLFOXIRI in metastatic colorectal cancer: a criticism from its native land. *Cancer Lett.* 2017 Aug 24. pii: S0304-3835(17)30512-8. doi: 10.1016/j.canlet.2017.08.025. [Epub ahead of print]

380. Grimaldi A, Zarone MR, Irace C, Zappavigna S, Lombardi A, Kawasaki H, Caraglia M, Misso G. Non-coding RNAs as a new dawn in tumor diagnosis. *Semin Cell Dev Biol.* 2017 Jul 29. pii: S1084-9521(17)30258-6. doi: 10.1016/j.semcdb.2017.07.035. [Epub ahead of print]

381. Kawasaki H, Lombardi A, Caraglia M Determination of miRNAs from Cancer Stem Cells Using a Low Density Array Platform. *.Methods Mol Biol.* 2018;1692:149-156. doi: 10.1007/978-1-4939-7401-6\_14.

382. Hamzehzadeh L, Caraglia M, Atkin SL, Sahebkar A. Dickkopf homolog 3 (DKK3): A candidate for detection and treatment of cancers? *J Cell Physiol.* 2018 Jun;233(6):4595-4605. doi: 10.1002/jcp.26313. Epub 2018 Jan 15. Review.

383. Alaia C, Boccellino M, Zappavigna S, Amher E, Quagliuolo L, Rossetti S, Facchini G, Caraglia M. Ipilimumab for the treatment of metastatic prostate cancer. *Expert Opin Biol Ther.* 2018 Feb;18(2):205-213. doi: 10.1080/14712598.2018.1420777. Epub 2017 Dec 28. Review.

384. Ristori S, Grillo I, Lusa S, Thamm J, Valentino G, Campani V, Caraglia M, Steiniger F, Luciani P, De Rosa G. Structural Characterization of Self-Assembling Hybrid Nanoparticles for Bisphosphonate Delivery in Tumors. *Mol Pharm.* 2018 Mar 5;15(3):1258-1265. doi: 10.1021/acs.molpharmaceut.7b01085. Epub 2018 Feb 20.

385. Di Martino MT, Zazzeroni F, Donadelli M, Chiodoni C, Caraglia M, Scotlandi K, Meschini S, Leonetti C. Reprogramming Tumor-Immune Cell Interface in Solid and Hematological Malignancies to Enhance Response to Therapy. *J Exp Clin Cancer Res.* 2018 Mar 5;37(1):48. doi: 10.1186/s13046-018-0710-x. No abstract available.

386. Hosseinpour-Moghaddam K, Caraglia M, Sahebkar A. Autophagy induction by trehalose: Molecular mechanisms and therapeutic impacts. *J Cell Physiol.* 2018 Sep;233(9):6524-6543. doi: 10.1002/jcp.26583. Epub 2018 Apr 16. Review.

387. Grassia V, Lombardi A, Kawasaki H, Ferri C, Perillo L, Mosca L, Delle Cave D, Nucci L, Porcelli M, Caraglia M. Salivary microRNAs as new molecular markers in cleft lip and palate: a new frontier in molecular medicine. *Oncotarget.* 2018 Apr 10;9(27):18929-18938. doi: 10.18632/oncotarget.24838. eCollection 2018 Apr 10.

388. Correale P, Botta C, Staropoli N, Nardone V, Pastina P, Ulivieri C, Gandolfo C, Baldari TC, Lazzi S, Ciliberto D, Giannicola R, Fioravanti A, Giordano A, Zappavigna S, Caraglia M, Tassone P, Pirtoli L, Cusi MG, Tagliaferri P. Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine. *Oncotarget.* 2018 Apr 17;9(29):20539-20554. doi: 10.18632/oncotarget.24993. eCollection 2018 Apr 17

389. Mele L, Paino F, Papaccio F, Regad T, Boocock D, Stiuso P, Lombardi A, Liccardo D, Aquino G, Barbieri A, Arra C, Coveney C, La Noce M, Papaccio G, Caraglia M, Tirino V, Desiderio V. A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo. *Cell Death Dis.* 2018 May 1;9(5):572. doi: 10.1038/s41419-018-0635-5.

390. Ottaiano A, De Stefano A, Capozzi M, Nappi A, De Divitiis C, Romano C, Silvestro L, Cassata A, Casaretti R, Tafuto S, Caraglia M, Beretta M, Nasti G, Avallone A. First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis. *Front Pharmacol.* 2018 May 3;9:441. doi: 10.3389/fphar.2018.00441. eCollection 2018. Review.

391. Momtazi-Borojeni AA, Ghasemi F, Hesari A, Majeed M, Caraglia M, Sahebkar A. Anti-Cancer and Radio-Sensitizing Effects of Curcumin in Nasopharyngeal Carcinoma. *Curr Pharm Des.* 2018;24(19):2121-2128. doi: 10.2174/138161282466180522105202.

392. Scognamiglio P, Chiaradia G, Giovanetti M, Albertini E, Camoperagna A, Farinella M, Lorenzetti D, Oldrini M, Rancilio L, Caraglia A, Maraglino FP, Ippolito G, Girardi E. HIV rapid testing in community and outreach sites: results of a nationwide demonstration project in Italy. *BMC Public Health.* 2018 Jun 18;18(1):748. doi: 10.1186/s12889-018-5680-6.

393. Tatulli F, Delcuratolo A, Caraglia A, Notarnicola A, Carbone FPN, Caputi A. Three-trocar laparoscopic cholecystectomy under spinal anesthesia in a patient with asthma. *G Chir.* 2018 May-Jun;39(3):188-190.
394. Martano M, Stiuso P, Facchiano A, De Maria S, Vanacore D, Restucci B, Rubini C, Caraglia M, Ravagnan G, Lo Muzio L. Aryl hydrocarbon receptor, a tumor grade-associated marker of oral cancer, is directly downregulated by polydatin: A pilot study. *Oncol Rep.* 2018 Sep;40(3):1435-1442. doi: 10.3892/or.2018.6555. Epub 2018 Jul 10.
395. Orditura M, Della Corte CM, Diana A, Ciaramella V, Franzese E, Famiglietti V, Panarese I, Franco R, Grimaldi A, Lombardi A, Caraglia M, Santoriello A, Procaccini E, Lieto E, Maiello E, De Vita F, Ciardiello F, Morgillo F. Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs. *Breast.* 2018 Oct;41:165-171. doi: 10.1016/j.breast.2018.08.002. Epub 2018 Aug 4.
396. Ricciardiello F, Addeo R, Di Lullo AM, Abate T, Mazzone S, Oliva F, Motta G, Caraglia M, Mesolella M. Adenoid cystic carcinoma of the larynx in a 70-year-old patient: A case report. *Oncol Lett.* 2018 Sep;16(3):2783-2788. doi: 10.3892/ol.2018.8976. Epub 2018 Jun 18.
397. D'Arena G, Seneca E, Migliaccio I, De Feo V, Giudice A, La Rocca F, Capunzo M, Calapai G, Festa A, Caraglia M, Musto P, Iorio EL, Ruggieri V. Oxidative stress in chronic lymphocytic leukemia: still a matter of debate. *Leuk Lymphoma.* 2018 Sep 20:1-9. doi: 10.1080/10428194.2018.1509317.
398. Giarra S, Zappavigna S, Campani V, Abate M, Cossu AM, Leonetti C, Porru M, Mayol L, Caraglia M, De Rosa G. Chitosan-Based Polyelectrolyte Complexes for Doxorubicin and Zoledronic Acid Combined Therapy to Overcome Multidrug Resistance. *Pharmaceutics.* 2018 Oct 9;10(4). pii: E180. doi: 10.3390/pharmaceutics10040180.
399. Cordani M, Butera G, Dando I, Torrens-Mas M, Butturini E, Pacchiana R, Oppici E, Cavallini C, Gasperini S, Tamassia N, Nadal-Serrano M, Coan M, Rossi D, Gaidano G, Caraglia M, Mariotto S, Spizzo R, Roca P, Oliver J, Scupoli MT, Donadelli M. Mutant p53 blocks SESN1/AMPK/PGC-1 $\alpha$ /UCP2 axis increasing mitochondrial O<sub>2</sub><sup>-</sup> production in cancer cells. *Br J Cancer.* 2018 Oct;119(8):994-1008. doi: 10.1038/s41416-018-0288-2. Epub 2018 Oct 15.
400. Ilisso CP, Delle Cave D, Mosca L, Pagano M, Coppola A, Mele L, Caraglia M, Cacciapuoti G, Porcelli M S. Adenosylmethionine regulates apoptosis and autophagy in MCF-7 breast cancer cells through the modulation of specific microRNAs. *Cancer Cell Int.* 2018 Dec 4;18:197. doi: 10.1186/s12935-018-0697-6. eCollection 2018.

**H Index: 63 (Google Scholar) 53 (Scopus)**

**Impact factor: about 7000**

#### BOOK CHAPTERS

- 1) M. Caraglia, G. Meo, A. Budillon: "Fattori predittivi di tossicità correlata alla Chemioterapia: Carcinoma del Colon-Retto" in G. Tonini: "I fattori predittivi in oncologia" Il Pensiero Scientifico Editore, 2005.
- 2) M. Caraglia, A. Catalano, M. Marra, A. Budillon, A. Procopio: "Oxidative stress and activation of survival pathways as a basis for mesothelioma pathogenesis: new perspectives for experimental therapy" in A. Baldi ed.: "Mesothelioma: from bench side to the clinic" Nova Science Publishers, Inc. Hauppauge, NY. 2007.
- 3) A. Budillon , M Caraglia, E Di Gennaro, M Marra. "L'Apparato Respiratorio" in Balestrieri C. et al.eds. "Diagnostica Molecolare nella Medicina di Laboratorio", pp. 155-179. Piccin, Italy 2008
- 4) M. Caraglia and M. Marra. Cura del capitolo 13 "Il Metabolismo dei Lipidi II: vie Metaboliche di Lipidi particolari" dell'edizione italiana del *Textbook of biochemistry. With clinical correlations* di Devlin (Idelson - Gnocchi 6° edizione)
- 5) M. Caraglia, G. F. Nicoletti, A. Lombardi, G. Botti e R. Franco capitolo 3 in A . Baldi and al. Skin Cancer:A Pratical Approach "Cutaneous Squamous Cell Carcinoma: Focus on Biochemical and Molecular Characteristics" pp 29-57 Humana Press
- 6) R. Franco, A.M. Anniciello, G. Botti, M. Caraglia e A. Luce capitolo 5 in A . Baldi and al. Skin Cancer: A Pratical Approach "Basal Cell Carcinoma : Molecular and Pathological Features" pp 75-88 Humana Press
- 7) R. Franco, M.E Errico, F. Zito Marino, A.M. Anniciello, G. Botti, M. Caraglia e A. Grimaldi "Skin Adnexal Tumours: A Large Spectrum of Clinic- Pathological Lesions" pp 89-108 Humana Press

PATENTS

1. E. Novellino, P. Grieco, M. Caraglia, A. Budillon, R. Franco, SR Addeo. *Impiego di ligandi di natura peptidica e non peptidica del recettore UT dell'Urotensina-II quali marcatori di differenziazione del carcinoma prostatico umano.* FI2007A000032
2. E. Novellino, P. Grieco, M. Caraglia, A. Budillon, R. Franco, SR Addeo. *Use of non peptidic and peptidic ligands or immunodetection of the receptor for urotensin II for the definition of both differentiation and prognosis of human prostate adenocarcinoma.* PCT/EP2008/051541
3. M. Caraglia, G. De Rosa, A. Abbruzzese, M.I. La Rotonda, C. Leonetti, P. Tassone, G. Salzano, M. Marra. *Uso dell'acido zoledronico per la preparazione di formulazioni farmaceutiche per il trattamento del cancro della prostata e del mieloma multiplo.* FI2009A000190
4. M. Caraglia, G. De Rosa, A. Abbruzzese, M.I. La Rotonda, C. Leonetti, P. Tassone, G. Salzano, M. Marra. *Nanoparticelle autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori.* FI2010A000206.
5. Dipartimento di Medicina Sperimentale della Seconda Università di Napoli, A. Abbruzzese, M. Caraglia, G. De Rosa, M. I. La Rotonda, L. Luongo, G. Salzano, M. Marra, E. Palazzo, F. Rossi. *Uso di bisfosfonati per la preparazione di formulazioni farmaceutiche per il trattamento dei sintomi associati a dolore neuropatico.* NA2010A000046 del 28.09.2010
6. De Rosa G., Caraglia M., Tassone P., La Rotonda M.I., Abbruzzese Saccardi A., Salzano G., Marra M., Leonetti C. *Self-assembling nanoparticles for the release of bisphosphonates in the treatment of human cancers.* [WO2012042024].PCT/EP2011/067119
7. De Rosa G., Tassone P., Caraglia M., Tagliaferri P. *"Formulazione costituita da SNALP contenente pre-miR34a utile per il trattamento del mieloma multiplo"*FI2012A000025 del 14/02/2012